USRE37437E1 - Sheet-like diagnostic device - Google Patents

Sheet-like diagnostic device Download PDF

Info

Publication number
USRE37437E1
USRE37437E1 US08/544,579 US54457995A USRE37437E US RE37437 E1 USRE37437 E1 US RE37437E1 US 54457995 A US54457995 A US 54457995A US RE37437 E USRE37437 E US RE37437E
Authority
US
United States
Prior art keywords
analyte
zone
mpaz
layer
spzs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US08/544,579
Inventor
Heinz-Jürgen Friesen
Gerd Grenner
Hans-Erwin Pauly
Helmut Kohl
Klaus Habenstein
Joseph Stärk
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Siemens Healthcare Diagnostics GmbH Germany
Original Assignee
Dade Behring Marburg GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6252876&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=USRE37437(E1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to US08/544,579 priority Critical patent/USRE37437E1/en
Application filed by Dade Behring Marburg GmbH filed Critical Dade Behring Marburg GmbH
Assigned to BEHRING DIAGNOSTICS GMBH reassignment BEHRING DIAGNOSTICS GMBH SEE RECORDING ON REEL 8792, FRAME 0076. (RE-RECORD TO CORRECT THE NUMBER OF MICROFILM PAGES FROM 10 TO 15. Assignors: BEHRINGWERKE AKTIENGESELLSCHAFT
Assigned to BEHRING DIAGNOSTICS GMBH reassignment BEHRING DIAGNOSTICS GMBH ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BEHRINGWERKE AKTIENGESELLSCHAFT
Assigned to DADE BEHRING MARBURG GMBH reassignment DADE BEHRING MARBURG GMBH CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: BEHRING DIAGNOSTICS GMBH
Priority to US09/820,974 priority patent/USRE38688E1/en
Publication of USRE37437E1 publication Critical patent/USRE37437E1/en
Application granted granted Critical
Assigned to DRESDNER BANK AKTIENGESELLSCHAFT IN FRANKFURT AM MAIN reassignment DRESDNER BANK AKTIENGESELLSCHAFT IN FRANKFURT AM MAIN GRANT OF SECURITY INTEREST IN UNITED STATES PATENTS, TRADEMARKS AND OTHER INTELLECTUAL PROPERTY RIGHTS Assignors: DADE BEHRING MARBURG GMBH
Assigned to DADE BEHRING MARBURG GMBH reassignment DADE BEHRING MARBURG GMBH RELEASE OF SECURITY INTEREST Assignors: DRESDNER BANK AKTIENGESELLSCHAFT IN FRANKFURT AM MAIN
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/52Use of compounds or compositions for colorimetric, spectrophotometric or fluorometric investigation, e.g. use of reagent paper and including single- and multilayer analytical elements
    • G01N33/521Single-layer analytical elements
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/52Use of compounds or compositions for colorimetric, spectrophotometric or fluorometric investigation, e.g. use of reagent paper and including single- and multilayer analytical elements
    • G01N33/525Multi-layer analytical elements
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54366Apparatus specially adapted for solid-phase testing
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/558Immunoassay; Biospecific binding assay; Materials therefor using diffusion or migration of antigen or antibody
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00Chemistry: molecular biology and microbiology
    • Y10S435/805Test papers
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00Chemistry: molecular biology and microbiology
    • Y10S435/81Packaged device or kit
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00Chemistry: molecular biology and microbiology
    • Y10S435/962Prevention or removal of interfering materials or reactants or other treatment to enhance results, e.g. determining or preventing nonspecific binding
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00Chemistry: molecular biology and microbiology
    • Y10S435/97Test strip or test slide
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00Chemistry: analytical and immunological testing
    • Y10S436/807Apparatus included in process claim, e.g. physical support structures
    • Y10S436/81Tube, bottle, or dipstick

Definitions

  • the invention relates to a solid diagnostic device which comprises several functional sectors and is used for the detection and quantitative determination of substances or analytes in biological fluids.
  • the invention also relates to a process using this device in which, after the device has come into contact with the fluid, the analytes react with specific combination partners having biological affinity and am detected by means of labelling reagents.
  • the ability to identify and estimate specific compounds has made it possible to monitor the administration of medicaments, the quantification of physiologically active compounds or secondary products thereof and the diagnosis of infections.
  • the immunoassay methods (RIA, ELSIA ELISA and the agglutination test) are of particular importance.
  • the specific combination reactions utilized in the tests are not limited to immunological interactions, such as antigen-antibody or hapten-antibody interactions, but also utilize interactions having biological affinity, such as lectin-sugar or active compound-receptor.
  • Integrated dry chemical test elements such as are described in the present invention, simplify the performance of the tests and shorten the test times.
  • each zone is readily accessible both from above and also from below, for a determination and also for the addition of reagents which may perhaps be required.
  • the invention relates to a sheet-like diagnostic device which contains all the reagent components and which contains not only all the components required for the functional sequence, but also the functional sequences themselves in an integrated form, and by means of which it is possible to detect an analyte having properties of biological affinity, in such a way that a solution of the analyte is brought into contact with a functional region of the device designed for this purpose, and the analyte as detected via a signal-producing system in a single functional region, a solid phase zone.
  • a second analyte, or further analytes, as constituents of the same solution can be detected at the same time by means of the device, if these analytes possess properties of biological affinity different from the hit analyte. They are also detected in the same manner as the first analyte in a single functional region, a solid phase zone appropriate for them.
  • the functional regions for the detection of the second or further analytes are situated on the sheet-like device in front of or behind the functional region for the detection of the first analyte.
  • the device can also contain several solid phase zones which are appropriate for an analyte and different measurement ranges of this analyte.
  • the device contains all reactants and reagents in a dehydrated form.
  • FIG. 1 is a summary table illustrating test assemblies according to certain preferred embodiments of the present invention.
  • FIG. 2 is a summary table illustrating test assemblies according to certain preferred embodiments of the present invention.
  • the sheet-like diagnostic device comprises one or several strips arranged behind one another, of material which have a capacity for absorbing aqueous solutions.
  • the strips are fixed on a solid support. They contain the reagent components required for the particular diagnostic agent and thus become functional sectors or functional regions.
  • the functional sector situated at one end of the strip-shaped device (solvent application zone) is brought into contact with the analyte solution by being dipped into the latter or by the application of the latter.
  • the solution migrates through all the functional regions.
  • the absorptive capacity of the supporting materials of which the strips are composed causes a flow of liquid which stops at the other end of the strip-shaped device.
  • the analyte can also be applied in the middle region of the device, and a flow of liquid from one end of the device to the other can then be induced.
  • the sample does not have to be applied directly to the chromatographing section of the device. It can also be applied to an absorptive material which is situated on the device and has the function of removing blood cells from the sample. After being filtered the sample then reaches the device. In the course of this filtration process the addition of reagents can be effected at the same time by dissolving the latter out of components present in the filter in a dry state. Interfering factors can be eliminated from the solution by means of such components.
  • the ascorbic acid present in a sample which interferes in the use of oxidases and peroxidases as labelling agents, can be rendered harmless by means of a suitable oxidizing agent.
  • the filter can also have the function of an adsorbent which removes interfering factors from the sample by adsorption.
  • the filtration, adsorption and reagent admixing function for conditioning the sample for the test can also be taken over by the mobile phase application zone or a zone situated behind the latter.
  • the distribution of the solvent in the individual functional regions depends on the adsorptive capacity and the dimensions of the materials used.
  • the solvent application zone can have be function of a volume metering element, as described in German Patent Nos. 3,043,608 and 2,332,760, and U.S. Pat. Nos. 3,464,560, 3,600,306, 3,667,607, 3,902,847, 4,144,306 and 4,258,001. It can contain, in dry form, the various reagents required for the function of the test element.
  • the solvent application zone can be a piece of fabric paper which is located at one end of the test element and which becomes completely saturated with a definite volume of liquid merely by being dipped into a solution, for example a solution of the sample, or by being briefly flushed with tap water, and then releases the liquid to the succeeding zones more slowly and in a controlled manner.
  • the solvent application zone has dimensions such that it takes up sufficient liquid to permit the latter to migrate to the other end of the device, the end of the absorption zone.
  • the absorption zone has the function of absorbing excess and freely mobile reagent components and reaction products of the single signal-producing system.
  • the absorbent supporting materials in the form of one or more strips, as constituents of the various functional regions, can, according to choice, be composed of cellulose, of chemical derivatives of cellulose or of plastics having a porous or fibrous structure and adequately hydrophilic properties, or of particles such as cellulose or silica gel embedded in a synthetic membrane, and also of natural products which are hydrophillic hydrophilic but have been rendered insoluble in water.
  • a combination of strips composed of different materials can be used. Suitable absorbent materials are selected on the basis of the requirements set for the particular diagnostic device.
  • Reactants with immunological binding properties such as antigens, haptens or antibodies are incorporated in various embodiments of the device.
  • one reactant having biological affinity can be the specific lectin
  • the second reactant having immunological affinity can be an antibody which is directed against a point of attachment on the analyte other than that of the lectin.
  • One one combination partner can be the receptor substance for the active compound
  • the second combination partner can be an antibody which is directed against another point of attachment on the active compound.
  • the other combination partner(s) are present in the supporting materials. They are provided with a labelling.
  • enzyme labelling is preferred. It requires chromogenic substrate systems or substrate systems which produce fluorescence or chemiluminescence.
  • Chemiluminescence labelling represents a further example of a labelling which is only measured after the addition of a reagent. It is possible to measure either the chemiluminescence itself or a fluorescence excited by the latter. In most cases fluorescence labelling is measured without the addition of a reagent being required. However, as in the use of certain rare earth chelates, it can also be desirable to produce the fluorophore to be measured only as the result of adding a reagent, or to add a second fluorophore which becomes excited by the first or which excites the first fluorophore. The fluorescence can be measured at one point, as a function of time or as fluorescence polarization.
  • a reagent required for detection can be induced to react with the immune complex to be detected in various ways, after the separation stage.
  • Part of the signal-producing system can be located in the sold solid phase zone.
  • a reagent required to detect the labelling can be released at a retarded rate in various embodiments in the heterogeneous immunoassay with detection in the bound phase.
  • the application of reagents by means of a stream of liquid arranged parallel to the main stream of liquid, but flowing more slowly and starting from the mobile phase reservoir and entering in front of the zone containing the labelled component.
  • the parallel stream of liquid can be controlled by using an absorbent medium which chromatographs more slowly, for example a paper which chromatographs suitably slowly or a paper which is impregnated in places with “components temporarily blocking the way”, such as, for example, polymers which impart a high viscosity on passing into solution (for example polyvinyl alcohols or dextrans).
  • the application of reagents can be effected by pressing down an element which is a solid constituent of the test element.
  • the “pressing down” can be effected mechanically or by removing distance pieces by the action of a stream of liquid.
  • the mechanical pressing down of an element containing the reagents can be effected by pressing down a flap or a piece of paper supported by distance pieces.
  • the lowering of an element containing the reagents by the action of the stream of liquid can be effected, for example, by laminating over one another the solid phase, a water-soluble polymer and the reagent carrier (for example a suitably impregnated piece of paper).
  • a retarded introduction of reagents into the liquid stream can be effected using a microencapsulated reagent which only emerges from the encapsulation after the solid phase has been adequately washed, or by coating the reagent adhering in the matrix with components which dissolve slowly.
  • a reagent for detecting the labelling is produced by a delay circuit, making use of an enzyme.
  • the color formation in the solid phase zone only begins after this zone has been adequately washed free from nonspecifically bound labelling by the strewn of liquid.
  • the components fixed there can be attached by chemical covalent bonds or adsorptively to an absorptive support which is a part of the test element.
  • These components can also be attached to a dispersion of particles which remain fixed at the place of application after they have been applied to an absorbent support.
  • suspensions of cells carrying specific receptors on their surface such as, for instance, Staphylococcus aureus Cowan I cells, or latex particles carrying combination partners of biological affinity attached to their surface, are suitable for being fixed in a paper matrix.
  • the components of the test strip which are attached to pipettable supports and also the unattached components of the device can be dried onto the absorbent matrix of the element by air drying; freeze-drying stages are not absolutely necessary.
  • test performance will be illustrated as examples of embodiments which can be regarded as independent of the labelling used. For the sake of simplicity, they are only described for the detection of a single analyte by means of the diagnostic device.
  • the solid phase combination partner is attached by covalent bonds or adsorptively to the supporting material of the solid phase functional region.
  • the solution of analyte renders mobile a predetermined amount of labelled analyte contained in the diagnostic agent.
  • the two components migrate into the functional sector containing the solid phase combination partner and compete for combination with the solid phase combination partner. If the proportion of analyte is high compared with the labelled analyte, little labelled analyte will be attached. if it is low, a great deal of labelled analyte will be attached.
  • the solid phase combination partner is housed as an unattached component in a functional region in front of the solid phase functional region.
  • the oncoming front of solvent transports it into the solid phase functional region, where it becomes attached
  • This solid phase attachment is produced by combination systems of biological affinity which are independent of the combination system of the analyte.
  • a combination partner which is conjugated with biotin attaches itself to avidin attached to the support.
  • An immunoglobulin, such as IgG, as a combination partner, is fixed via its Fc component to support-attached protein A of S. aureus, or is attached by solid phase antibody of another species, non idiotypically directed to said immunoglobulin.
  • the analyte and the labelled analyte compete, as constituents of the diagnostic agent for the attachments to the solid phase combination partner during the processing period.
  • This competition reaction takes place partly with the dissolved solid phase combination partner and partly with the solid phase combination partner which has already been attached to the solid phase.
  • the analyte forms, with the labelled combination partner, a binary complex which migrates together with the solvent into the solid phase functional region and reacts there with the solid phase combination partner, with the formation of a ternary complex, attached to the solid phase, which can be detected via the labelling of the first combination partner.
  • the excess labelled combination partner is removed by the solvent into the subsequent functional region, the absorption zone.
  • the two reactants of the analyte of biological affinity are housed in the functional regions in such a way that the analyte reacts simultaneously or successively with both reactants and the resulting ternary complex then migrates into the solid phase functional region, where, as already described above, it becomes attached to the solid phase via a second system of biological affinity which is independent of that of the analyte.
  • FIGS. 1 and 2 illustrate in an exemplary manner the distribution of the components of the agent in the functional regions and, after the performance of the reaction, the composition of the solid phase complex, the amount of which is a measure of the concentration of analytes in the sample.
  • the chromatography time for the test element is not more than 16 minutes. Evaluation can also be carried out visually.
  • HCG as analyte
  • the start of the range of determination in an example using a glucose oxidase attached to a solid phase and a peroxidase labelling was 0.3 ng/ml (corresponding to 3 U/liter).
  • HCG having a specific activity of approx. 3000 U/mg was obtained from Organon. Peroxidase from horseradish was obtained from Bochringer Mannheim (catalog no. 413,470). The hetero-bifunctional reagent N- ⁇ -maleimidobutyryloxysuccinimide (GMBS) was obtained from Behring Diagnostics and was reacted with the HCG as described by Tranimori et al., 1983, in J. Imm. Meth. 62, 123-131. 2-iminothiolane hydrochloride (Sigma, catalog no. I 6256) was reacted with peroxidase as described by King et al., 1978, in Biochemistry 17, 1499-1506.
  • GMBS N- ⁇ -maleimidobutyryloxysuccinimide
  • a conjugate was prepared from the GMBS-HCG and the iminothiolane-peroxidase as described by Tanimori et al.
  • the crude conjugate was purified by gel chromatography over Ultrogel ACA 44 (LKB). The fraction in which about 1-2 peroxidase molecules were coupled per HCG molecule was used for the test.
  • the conjugate was diluted with Enzygnost IgE incubation medium made by Behringwerke, order no. OS D, designated briefly as incubation medium in the following text.
  • Antibodies against HCG were obtained by immunizing rabbits, and antibodies against rabbit-IgG were obtained by immunizing goats.
  • the IgG fractions were isolated from serum by ammonium sulfate precipitation and anion exchange chromatography, and were purified further by immunadsorption. The methods used are described in the book “Immunsammlung vonmethoden” (Immunological working methods), Helmut Friemel, Editor, 1984, Gustav Fischer Verlag, Stuttgart.
  • the anti-HCG antibody was finally diluted in the conjugate dilution buffer indicated above.
  • Glucose oxidase from Aspergillus niger was obtained as a solution containing 300 U/mg (Serva, catalog No. 22,737). The glucose oxidase was finally diluted with incubation medium.
  • ⁇ -D-glucose and tetramethylbenzidine hydrochloride were obtained from Serva, catalog no. 22,720 and 35,926, respectively.
  • the sheet-like functional regions were prepared as follows:
  • the mobile phase application zone was prepared by cutting, to dimensions of 20 ⁇ 6 mm, a fabric sponge cloth made by Kalle; this is a synthetic sponge of regenerated cellulose which has been compressed in a dry state. It was impregnated with a solution of 50 mg of glucose and 0.75 mg of tetramethylbenzidine hydrochloride per ml of water, and was dried in a stream of air.
  • the conjugate, the anti-HCG antibody and glucose oxidase (5 ⁇ l of each at 25 ⁇ l/ml, 100 ⁇ l/ml and 0.1 mg/ml, respectively) were applied behind one another, at uniform distance, to a 45 ⁇ 5 mm, piece of MN no. 1 paper (Macherey & Nagel), and were dried in the air.
  • a piece measuring 5 ⁇ 5 mm of Schleicher & Schull No. 597 paper was coated in a covalent manner with anti-rabbit IgG-antibody as the solid phase zone. This was effected by coupling the antibody with the paper, which had been activated with cyanogen bromide, as described by Clarke et al., 1979, Meth.Enzymology, volume 68, 441-442.
  • double-sided adhesive tape Tesaband made by Beiersdorf
  • the test was carried out in each case by applying 200 ⁇ l of an HCG dilution in incubation medium to the fabric.
  • the chromatographic development of the test element and the self-actuating color development were complete after 15 minutes at room temperature, and evaluation could be carried out either visually or by means of a reflectometer.
  • HCG concentration (mg of glucose per dl of (U/liter) blood) 0.3 107 3 117 30 95 300 70 3000 0
  • test strip assembly shown here can also be achieved if the glucose oxidase and the anti-HCG antibody are located in the same zone.
  • the test strip which is correspondingly shorter, then renders the result after approx. 10 minutes.

Abstract

A solid diagnostic device for the quantitative determination of substances of biological affinity in biological fluids is described. A process is also described in which the biological fluid is brought into contact with a specific functional sector of the device, the fluid migrates through several functional sectors situated beside one another and containing suitable reagent components, and one or more substances of biological affinity are detected in such functional sectors which contain, for each substance to be detected, at least one combination partner of biological affinity, attached to a solid phase.

Description

The invention relates to a solid diagnostic device which comprises several functional sectors and is used for the detection and quantitative determination of substances or analytes in biological fluids. The invention also relates to a process using this device in which, after the device has come into contact with the fluid, the analytes react with specific combination partners having biological affinity and am detected by means of labelling reagents.
In methods of diagnosis, the ability to identify and estimate specific compounds has made it possible to monitor the administration of medicaments, the quantification of physiologically active compounds or secondary products thereof and the diagnosis of infections. In this respect, the immunoassay methods (RIA, ELSIA ELISA and the agglutination test) are of particular importance. The specific combination reactions utilized in the tests are not limited to immunological interactions, such as antigen-antibody or hapten-antibody interactions, but also utilize interactions having biological affinity, such as lectin-sugar or active compound-receptor.
Although the existing tests are sensitive and specific, they do not constitute convenient application forms, because of the long duration of the test (in most cases several hours or even days) and the frequent test steps, such as immune reaction, washing steps and enzymatic reaction. The long test times are not compatible with use in emergency methods of diagnosis.
Integrated dry chemical test elements, such as are described in the present invention, simplify the performance of the tests and shorten the test times.
No sheet-like test element, in which all the components of the immune reaction of a heterogeneous immunoassay using solid phase detection, and the functional performance and the “bound-free” separation, are integrated has been described so far.
Whereas in the test strip assembly the immune reaction steps and the separation of bound and free phases are operated in the heterogeneous test by directed streams of liquid, in test element assemblies operating by means of thin layers laminated over one another (film technology), processes controlled by diffusion and directed by the concentration gradient are possible driving forces. A fluorescence labelling is used in German Offenlegungsschrift No. 3,329,728 (Japanese Patent No. P144,341/82) and EP A No. 0,097,952 (Japanese Patent No. 114,359/82). The labelling has a low molecular weight and hence promotes processes controlled by diffusion. However, the test has to be carried out at an elevated temperature. In the first of these two cases both the free phase and also the bound phase are evaluated. In film technology the absorption of solvent is effected either by hydrating swellable components or by filling capillary cavities. In the case Of assemblies having layers laminated over one another only the top layer and the bottom layer are accessible to detection without major difficulties.
After the reaction steps have taken place it is difficult to react reagents with components in intermediately placed layers. In the test strip assembly having zones situated one behind another, such as is used in the present invention, in principle each zone is readily accessible both from above and also from below, for a determination and also for the addition of reagents which may perhaps be required.
The invention relates to a sheet-like diagnostic device which contains all the reagent components and which contains not only all the components required for the functional sequence, but also the functional sequences themselves in an integrated form, and by means of which it is possible to detect an analyte having properties of biological affinity, in such a way that a solution of the analyte is brought into contact with a functional region of the device designed for this purpose, and the analyte as detected via a signal-producing system in a single functional region, a solid phase zone.
A second analyte, or further analytes, as constituents of the same solution can be detected at the same time by means of the device, if these analytes possess properties of biological affinity different from the hit analyte. They are also detected in the same manner as the first analyte in a single functional region, a solid phase zone appropriate for them. The functional regions for the detection of the second or further analytes are situated on the sheet-like device in front of or behind the functional region for the detection of the first analyte. The device can also contain several solid phase zones which are appropriate for an analyte and different measurement ranges of this analyte. The device contains all reactants and reagents in a dehydrated form.
BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1 is a summary table illustrating test assemblies according to certain preferred embodiments of the present invention; and
FIG. 2 is a summary table illustrating test assemblies according to certain preferred embodiments of the present invention.
DESCRIPTION OF PREFERRED EMBODIMENTS
The sheet-like diagnostic device comprises one or several strips arranged behind one another, of material which have a capacity for absorbing aqueous solutions. The strips are fixed on a solid support. They contain the reagent components required for the particular diagnostic agent and thus become functional sectors or functional regions. The functional sector situated at one end of the strip-shaped device (solvent application zone) is brought into contact with the analyte solution by being dipped into the latter or by the application of the latter. The solution migrates through all the functional regions. The absorptive capacity of the supporting materials of which the strips are composed causes a flow of liquid which stops at the other end of the strip-shaped device. The analyte can also be applied in the middle region of the device, and a flow of liquid from one end of the device to the other can then be induced.
The sample does not have to be applied directly to the chromatographing section of the device. It can also be applied to an absorptive material which is situated on the device and has the function of removing blood cells from the sample. After being filtered the sample then reaches the device. In the course of this filtration process the addition of reagents can be effected at the same time by dissolving the latter out of components present in the filter in a dry state. Interfering factors can be eliminated from the solution by means of such components. Thus, for instance, the ascorbic acid present in a sample, which interferes in the use of oxidases and peroxidases as labelling agents, can be rendered harmless by means of a suitable oxidizing agent. Furthermore, the filter can also have the function of an adsorbent which removes interfering factors from the sample by adsorption. The filtration, adsorption and reagent admixing function for conditioning the sample for the test can also be taken over by the mobile phase application zone or a zone situated behind the latter.
The distribution of the solvent in the individual functional regions depends on the adsorptive capacity and the dimensions of the materials used.
`The solvent application zone can have be function of a volume metering element, as described in German Patent Nos. 3,043,608 and 2,332,760, and U.S. Pat. Nos. 3,464,560, 3,600,306, 3,667,607, 3,902,847, 4,144,306 and 4,258,001. It can contain, in dry form, the various reagents required for the function of the test element. The solvent application zone can be a piece of fabric paper which is located at one end of the test element and which becomes completely saturated with a definite volume of liquid merely by being dipped into a solution, for example a solution of the sample, or by being briefly flushed with tap water, and then releases the liquid to the succeeding zones more slowly and in a controlled manner. The solvent application zone has dimensions such that it takes up sufficient liquid to permit the latter to migrate to the other end of the device, the end of the absorption zone.
Between the solvent application zone and the absorption zone there are located the functional regions in which are contained reaction components for the performance of the test and in which all the reaction stages of the performance of the test take place. Part of the reaction components for the performance of the test can also be homed in be sample application zone. The absorption zone has the function of absorbing excess and freely mobile reagent components and reaction products of the single signal-producing system.
The absorbent supporting materials in the form of one or more strips, as constituents of the various functional regions, can, according to choice, be composed of cellulose, of chemical derivatives of cellulose or of plastics having a porous or fibrous structure and adequately hydrophilic properties, or of particles such as cellulose or silica gel embedded in a synthetic membrane, and also of natural products which are hydrophillic hydrophilic but have been rendered insoluble in water. A combination of strips composed of different materials can be used. Suitable absorbent materials are selected on the basis of the requirements set for the particular diagnostic device.
Reactants with immunological binding properties such as antigens, haptens or antibodies are incorporated in various embodiments of the device. In the event that glycoproteins or oligosaccharides which attach themselves to lectins are to be detected, one reactant having biological affinity can be the specific lectin, while the second reactant having immunological affinity can be an antibody which is directed against a point of attachment on the analyte other than that of the lectin. In the event that microbial active compounds are to be detected, One one combination partner can be the receptor substance for the active compound, while the second combination partner can be an antibody which is directed against another point of attachment on the active compound.
We combination partner having biological affinity becomes attached during the progress of the reaction, or has already been attached to the supporting material in the functional region designed for the detection of the analyte (solid phase zone). It is also called the solid phase combination partner. The other combination partner(s) are present in the supporting materials. They are provided with a labelling.
Amongst the various known possibilities of labelling, enzyme labelling is preferred. It requires chromogenic substrate systems or substrate systems which produce fluorescence or chemiluminescence. Chemiluminescence labelling represents a further example of a labelling which is only measured after the addition of a reagent. It is possible to measure either the chemiluminescence itself or a fluorescence excited by the latter. In most cases fluorescence labelling is measured without the addition of a reagent being required. However, as in the use of certain rare earth chelates, it can also be desirable to produce the fluorophore to be measured only as the result of adding a reagent, or to add a second fluorophore which becomes excited by the first or which excites the first fluorophore. The fluorescence can be measured at one point, as a function of time or as fluorescence polarization.
A reagent required for detection can be induced to react with the immune complex to be detected in various ways, after the separation stage. Part of the signal-producing system can be located in the sold solid phase zone. After the solid phase has been adequately washed, a reagent required to detect the labelling can be released at a retarded rate in various embodiments in the heterogeneous immunoassay with detection in the bound phase. The following are possible examples:
The application of reagents by means of a stream of liquid arranged parallel to the main stream of liquid, but flowing more slowly and starting from the mobile phase reservoir and entering in front of the zone containing the labelled component. The parallel stream of liquid can be controlled by using an absorbent medium which chromatographs more slowly, for example a paper which chromatographs suitably slowly or a paper which is impregnated in places with “components temporarily blocking the way”, such as, for example, polymers which impart a high viscosity on passing into solution (for example polyvinyl alcohols or dextrans).
After the solid phase has been adequately washed (=completion of chromatography), the application of reagents can be effected by pressing down an element which is a solid constituent of the test element. The “pressing down” can be effected mechanically or by removing distance pieces by the action of a stream of liquid. For example, the mechanical pressing down of an element containing the reagents can be effected by pressing down a flap or a piece of paper supported by distance pieces. The lowering of an element containing the reagents by the action of the stream of liquid can be effected, for example, by laminating over one another the solid phase, a water-soluble polymer and the reagent carrier (for example a suitably impregnated piece of paper).
A retarded introduction of reagents into the liquid stream can be effected using a microencapsulated reagent which only emerges from the encapsulation after the solid phase has been adequately washed, or by coating the reagent adhering in the matrix with components which dissolve slowly.
One possible means presented for the special case of enzyme labelling is as follows: when a peroxidase labelling is used, a glucose oxidase zone can be placed in from of the solid phase zone. Glucose and also the chromogen are then incorporated into the liquid stream, which can result in color formation behind the glucose oxidase. Appreciable color formation is only observed if, at an appropriately high concentration of peroxidase, sufficient H2O2 is formed by the oxidase. This formance of the peroxide sets in slowly, reaches an optimum concentration and finally reaches a high concentration which results in inhibition of the enzyme and this automatic cessation of the color formation. This coloration can be moderated if an H2O2-acceptor, for example a thioether as a mild reducing agent, or the enzyme catalase is incorporated in the oxidase zone or in front of the latter.
In this example a reagent for detecting the labelling is produced by a delay circuit, making use of an enzyme. The color formation in the solid phase zone only begins after this zone has been adequately washed free from nonspecifically bound labelling by the strewn of liquid.
There are several possible means of preparing the solid phase zone. The components fixed there can be attached by chemical covalent bonds or adsorptively to an absorptive support which is a part of the test element. These components can also be attached to a dispersion of particles which remain fixed at the place of application after they have been applied to an absorbent support. For example, suspensions of cells carrying specific receptors on their surface, such as, for instance, Staphylococcus aureus Cowan I cells, or latex particles carrying combination partners of biological affinity attached to their surface, are suitable for being fixed in a paper matrix. The components of the test strip which are attached to pipettable supports and also the unattached components of the device can be dried onto the absorbent matrix of the element by air drying; freeze-drying stages are not absolutely necessary.
A few test performance will be illustrated as examples of embodiments which can be regarded as independent of the labelling used. For the sake of simplicity, they are only described for the detection of a single analyte by means of the diagnostic device.
The following two embodiments, which conform to the principle of competitive immunoassay, will be described for the case where the analyte has only a single combination point of biological affinity or only one combination point of biological affinity out of several is utilized:
The solid phase combination partner is attached by covalent bonds or adsorptively to the supporting material of the solid phase functional region. The solution of analyte renders mobile a predetermined amount of labelled analyte contained in the diagnostic agent. The two components migrate into the functional sector containing the solid phase combination partner and compete for combination with the solid phase combination partner. If the proportion of analyte is high compared with the labelled analyte, little labelled analyte will be attached. if it is low, a great deal of labelled analyte will be attached.
The solid phase combination partner is housed as an unattached component in a functional region in front of the solid phase functional region. The oncoming front of solvent transports it into the solid phase functional region, where it becomes attached This solid phase attachment is produced by combination systems of biological affinity which are independent of the combination system of the analyte. A combination partner which is conjugated with biotin attaches itself to avidin attached to the support. An immunoglobulin, such as IgG, as a combination partner, is fixed via its Fc component to support-attached protein A of S. aureus, or is attached by solid phase antibody of another species, non idiotypically directed to said immunoglobulin.
As previously described, the analyte and the labelled analyte compete, as constituents of the diagnostic agent for the attachments to the solid phase combination partner during the processing period. This competition reaction takes place partly with the dissolved solid phase combination partner and partly with the solid phase combination partner which has already been attached to the solid phase.
If two combination points of differing specificity are present in an analyte, several embodiments, conforming to the principle of sandwich immunoassay, of the diagnostic agent are conceivable. Two of these will also be illustrated below:
If the solid phase combination partner is attached by covalent bonds or adsorptively to the supporting material of the solid phase functional region, the analyte forms, with the labelled combination partner, a binary complex which migrates together with the solvent into the solid phase functional region and reacts there with the solid phase combination partner, with the formation of a ternary complex, attached to the solid phase, which can be detected via the labelling of the first combination partner. The excess labelled combination partner is removed by the solvent into the subsequent functional region, the absorption zone.
If the solid phase combination partner is present in a non-attached form in the diagnostic agent and is rendered mobile by the solvent, the two reactants of the analyte of biological affinity are housed in the functional regions in such a way that the analyte reacts simultaneously or successively with both reactants and the resulting ternary complex then migrates into the solid phase functional region, where, as already described above, it becomes attached to the solid phase via a second system of biological affinity which is independent of that of the analyte.
In order to illustrate the embodiments descried described above and further embodiments which conform to the immunometric test principle, the principle of indirect antibody detection or the ELA (enzyme-labelled-antigen) principle of immunoassay, FIGS. 1 and 2 illustrate in an exemplary manner the distribution of the components of the agent in the functional regions and, after the performance of the reaction, the composition of the solid phase complex, the amount of which is a measure of the concentration of analytes in the sample.
It has been found that a completely integrated test strip operating in accordance with the principle of heterogeneous immunoassay by means of solid phase detection is not only feasible in principle, but can, in addition, also be evaluated within a period of less than one hour, the quantification and the sensitivity of conventional RIAs or ELISAs being achieved. The detection of trace components in the range of 10−12 mol/liter has been made possible at reaction times of less than 30 minutes, at room temperature, the amounts of sample required being 10−16 mol, corresponding, for example, to approx. 1 pg. The arrangements described also enable tests of lower sensitivity requirements to be carried out, however. Standard curves over two to three decades were obtained when evaluation was carried out with the Sanoquell reflectometer (made by Quelle). The chromatography time for the test element, including complete color development, is not more than 16 minutes. Evaluation can also be carried out visually. With HCG as analyte, the start of the range of determination in an example using a glucose oxidase attached to a solid phase and a peroxidase labelling was 0.3 ng/ml (corresponding to 3 U/liter).
In the example following, the application of the principle of the competitive double antibody test is presented as a concrete embodiment. In this test configuration, four components have to be reacted successively for the determination reaction and the separation stage, the reaction times and the concentrations of the reactant being critical values. The example is not to be regarded as limiting in any way, but merely serves to illustrate the subject of the invention further.
EXAMPLE
Completely integrated enzyme-immunochemical device for the detection of HCG by means of a built-in chromogen substrate system.
1.1. Reagents 1.1.1. HCG-peroxidase conjugate
HCG having a specific activity of approx. 3000 U/mg was obtained from Organon. Peroxidase from horseradish was obtained from Bochringer Mannheim (catalog no. 413,470). The hetero-bifunctional reagent N-λ-maleimidobutyryloxysuccinimide (GMBS) was obtained from Behring Diagnostics and was reacted with the HCG as described by Tranimori et al., 1983, in J. Imm. Meth. 62, 123-131. 2-iminothiolane hydrochloride (Sigma, catalog no. I 6256) was reacted with peroxidase as described by King et al., 1978, in Biochemistry 17, 1499-1506. A conjugate was prepared from the GMBS-HCG and the iminothiolane-peroxidase as described by Tanimori et al. The crude conjugate was purified by gel chromatography over Ultrogel ACA 44 (LKB). The fraction in which about 1-2 peroxidase molecules were coupled per HCG molecule was used for the test. The conjugate was diluted with Enzygnost IgE incubation medium made by Behringwerke, order no. OS D, designated briefly as incubation medium in the following text.
1.1.2. Antibodies
Antibodies against HCG were obtained by immunizing rabbits, and antibodies against rabbit-IgG were obtained by immunizing goats. The IgG fractions were isolated from serum by ammonium sulfate precipitation and anion exchange chromatography, and were purified further by immunadsorption. The methods used are described in the book “Immunologische Arbeitsmethoden” (Immunological working methods), Helmut Friemel, Editor, 1984, Gustav Fischer Verlag, Stuttgart. The anti-HCG antibody was finally diluted in the conjugate dilution buffer indicated above.
1.1.3. Glucose oxidase
Glucose oxidase from Aspergillus niger was obtained as a solution containing 300 U/mg (Serva, catalog No. 22,737). The glucose oxidase was finally diluted with incubation medium.
1.1.4. Glucose and Tetramethylbenzidine
α-D-glucose and tetramethylbenzidine hydrochloride were obtained from Serva, catalog no. 22,720 and 35,926, respectively.
1.2. Preparation of the Device
The sheet-like functional regions were prepared as follows:
The mobile phase application zone was prepared by cutting, to dimensions of 20×6 mm, a fabric sponge cloth made by Kalle; this is a synthetic sponge of regenerated cellulose which has been compressed in a dry state. It was impregnated with a solution of 50 mg of glucose and 0.75 mg of tetramethylbenzidine hydrochloride per ml of water, and was dried in a stream of air.
The conjugate, the anti-HCG antibody and glucose oxidase (5 μl of each at 25 μl/ml, 100 μl/ml and 0.1 mg/ml, respectively) were applied behind one another, at uniform distance, to a 45×5 mm, piece of MN no. 1 paper (Macherey & Nagel), and were dried in the air.
A piece measuring 5×5 mm of Schleicher & Schull No. 597 paper was coated in a covalent manner with anti-rabbit IgG-antibody as the solid phase zone. This was effected by coupling the antibody with the paper, which had been activated with cyanogen bromide, as described by Clarke et al., 1979, Meth.Enzymology, volume 68, 441-442.
A 20×5 mm. piece of Schleicher & Schüll No. 2668/8 paper was used as the absorption zone.
The four pieces of paper, with a 0.5-1 mm overlap behind one another, were fixed on a plastic ribbon by means of double-sided adhesive tape (Tesaband made by Beiersdorf), so that a test strip 5 mm wide was formed.
1.3. Performance of the Test
The test was carried out in each case by applying 200 μl of an HCG dilution in incubation medium to the fabric.
1.4 Results
The chromatographic development of the test element and the self-actuating color development were complete after 15 minutes at room temperature, and evaluation could be carried out either visually or by means of a reflectometer.
The following values were obtained when evaluating the solid phase zone (No. 597 paper) with the Sanoquell blood glucose evaluation apparatus made by Quelle:
Measured values
HCG concentration (mg of glucose per dl of
(U/liter) blood)
0.3 107
3 117
30 95
300 70
3000 0
The following values were obtained with the same test strips using the Rapimat urine test strip evaluation apparatus made by Behringwerke:
HCG concentration Measured values
(U/liter) (BIT)
0.3 76
3 76
30 94
300 119
3000 39
The test strip assembly shown here can also be achieved if the glucose oxidase and the anti-HCG antibody are located in the same zone. The test strip, which is correspondingly shorter, then renders the result after approx. 10 minutes.

Claims (34)

We claim:
1. An analytical device for the detection or determination of a component components in a fluid wherein said component is an analyte with bioaffinity binding properties, components are a plurality of analytes, said analytes including at least one attachment point of biological affinity, comprising a layer of a plurality of substantially planar zones adjacent one another and in absorbent contact with one another, said layer including:
a mobile phase application zone (MPAZ),
an intermediate zone (IZ), and
an adsorption zone (AZ),
liquid beingwherein said fluid is capable of moving by adsorption from said MPAZ through said IZ to said AZ, and wherein said IZ further comprises a plurality of solid phase zone (SPZ)zones (SPZs) for the detection of a plurality of analytes, said SPZs having at least one unlabelled reactant, capable of interactions of biological affinity with at least one analyte;, each of said SPZs being adjacent one another in said layer and each of said SPZs including said unlabelled reactants fixed thereto, said unlabelled reactants of each SPZ being specific for a specific analyte to be detected in each of said SPZs;
at least one unattached, labelled reactant (conjugate) , capable of interactions of biological affinity with said at least one analyte, disposed in an area between said the MPAZ and the SPZ SPZs; and
an analyte application zone disposed at said MPAZ or in between said MPAZ and said AZ, wherein after application of said at least one analyte, said at least one analyte is reacted with said reactants in said layer and is detected in said layer.
2. A device as claimed in claim 1, wherein the MPAZ has the function of a volume metering element and releases to the subsequent zones at least sufficient liquid for the liquid, controlled by capillary forces, to reach the end of the AZ.
3. A device as claimed in claim 1, wherein the MPAZ is a plastic sponge or a particulate layer which is composed of hydrophilic polymers and which is capable of containing chemicals, buffer substances or other substances required for certain tests.
4. A device as claimed in claim 1, wherein the analyte application zone retains blood cells.
5. A device as claimed in claim 1, wherein all or some of the reagents required for the detection of the labelling are present in one or more of substantially planar zones of the device.
6. A device a claimed in claim 1, wherein said at least one unlabelled reactant is fixed to said SPZ by means of covalent bonds.
7. A device as claimed in claim 1, wherein said at least one unlabelled reactant is fixed to said SPZ by means of absorption.
8. A device as claimed in claim 1, wherein said at least one unlabelled reactant is fixed to said SPZ by means of an interaction of biological affinity.
9. A device as claimed in claim 1, further including a plurality of solid phase zones (SPZs) for the detection of a plurality of analytes, said analytes including at least one attachment point of biological affinity each of said SPZs being adjacent one another in said layer and each of said SPZs including said unlabelled reactants fixed thereto, said unlabelled reactants of each SPZ being specific for a specific analyte to be detected in each of said SPZs.
10. A device as claimed in claim 1, wherein said layer includes a chromotographing section in at least a portion of said substantially planar zones, and further including a sample application zone laminated onto at least a portion of said chromatographing section and in adsorptive contact therewith.
11. A device as claimed in claim 1, wherein said layer includes a chromotographing section in at least a portion of said substantially planar zones, and further including a reagent zone laminated onto at least a portion of said chromotographing section and in adsorptive contact therewith, wherein at least some of the reagents required for the detection of the labelling are present in said reagent zone.
12. A process for the detection or determination of a component in a fluid wherein said component is an analyte with bioaffinity binding properties by rehydrating or solvating reactants and reagents by the fluid containing the analyte or by an additional fluid, said reactants and reagents being present in a dehydrated state in an analytical device for the detection or determination of a component in a fluid wherein said component is an analyte with bioaffinity binding properties, comprising a layer of a plurality of substantially planar zones adjacent one another and in absorbent contact with one another, said layer including:
a mobile phase application zone (MPAZ), an intermediate zone (IZ) and an adsorption zone (AZ), liquid being capable of moving by adsorption from said MPAZ through said IZ to said AZ, and wherein said IZ further comprises a solid phase zone (SPZ) having at least one unlabelled reactant, capable of interactions of biological affinity with at least one analyte;
at least one unattached, labelled reactant (conjugate), capable of interactions of biological affinity with said at least one analyte, disposed in an area between the MPAZ and the SPZ; and
an analyte application zone disposed at said MPA or in between said MPAZ and said AZ,
said process comprising:
applying a sample to said analyte application zone, reacting the at least one analyte in the sample in said layer and detecting said at least one analyte in said layer.
13. The process as claimed in claim 12, wherein, after the liquid sample containing the analyte has been fed to the MPAZ or after the sample has been fed to a sample application zone and a mobile phase has been fed to the MPAZ, the liquid reaches the end of the AZ, under the control of capillary forces, and reactions between reactants contained in the device and the analyte are thereby set in operation, and, after the labelled reactants which are not attached to the solid phase have been removed chromatographically, the amount of the labelling in the solid phase zone, which is a measure of the analyte concentration in the sample, is determined.
14. The process as claimed in claim 11 wherein the reactions taking place in the device are based on the principals of at least one of immunological detection reactions, competitive immunometric or sandwich immunoassay, indirect antibody detection by means of a labelled antibody and antibody detection by means of a labelled antigen.
15. The process as claimed in claim 12, wherein said detecting includes using a fluorophor as a labelling agent which is detected or measured directly or is detected or measured after the addition of a reagent present in the device, or a fluorophor which is detected or measured directly or after the addition of a further reagent is formed from the labelling agent by the addition of a reagent present in the device.
16. The process as in claim 12, wherein said detecting includes using a compound which can be excited to give chemiluminescence as a labelling agent, the chemiluminescence being detectable or measurable after the addition of a reagent present in the device.
17. The process as claimed in claim 12, wherein said detecting includes using an enzyme as a labelling agent, the activity of which is determined with the aid of a reagent present in the device.
18. An analytical device for the detection or determination of a component components in a fluid wherein said component is an analyte with bioaffinity binding properties components are a plurality of analytes, said analytes including at least one attachment point of biological affinity, comprising a layer of a plurality of substantially planar zones adjacent one another and in absorbant absorbent contact with one another, said layer including:
a mobile phase application zone (MPAZ),
an intermediate zone (IZ), and
an adsorption zone (AZ),
liquid beingwherein said fluid capable of moving by adsorption from said MPAZ through said IZ to said AZ, and wherein said IZ further comprises a plurality of solid phase zone (SPZ)zones (SPZs) for the detection of a plurality of analytes, each of said SPZs being capable of having at least one unlabelled reactant fixed thereto which is capable of interactions of bioaffinity with at least one analyte, during analysis said at least one unlabelled reactant being fixed to at least one second reactant which is fixed to said solid phase zone, each of said SPZs being adjacent one another in said layer, said unlabelled reactants of each SPZ being specific for a specific analyte to be detected in each of said SPZs;
at least one unattached labelled reactant (conjugate) , capable of interactions of biological affinity with said at least one analyte, disposed in an area between said MPAZ and said SPZ SPZs; and
an analyte application zone disposed at said MPAZ or in between said MPAZ and said AZ wherein after application of said at least one analyte, said at least one analyte is reacted with said reactants in said layer and is detected in said layer.
19. A device as claimed in claim 18, wherein said at least one second reactant is fixed to said SPZ by means of covalent bonds.
20. A device as claimed in claim 18, wherein said at least one second reactant is fixed to said SPZ by means of adsorption.
21. A device as claimed in claim 18, wherein said at least one second reactant is fixed to said SPZ by means of an interaction of biological affinity.
22. A device as claimed in claim 18, further including a plurality of solid phase zones (SPZs) for the detection of a plurality of analytes, mid analytes including at least one attachment point of biological affinity, each of said SPZs being adjacent one another in said layer and each of said SPZs including said unlabelled reactants fixed thereto, said unlabelled reactants of each SPZ being specific for a specific analyte to be detected in each of said SPZs.
23. A device as claimed in claim 18, wherein the MPAZ has the function of a volume metering element and releases to the subsequent zones at least sufficient liquid for the liquid, controlled by capillary forces, to reach the end of the AZ.
24. A device as claimed in claim 18, wherein the MPAZ is a plastic sponge or a particulate layer which is composed of hydrophilic polymers and which is capable of containing chemicals, buffer substances or other substances required for certain tests.
25. A device as claimed in claim 18, wherein the analyte application zone retains blood cells.
26. A device as claimed in claim 18, wherein said layer includes a chromotographing section in at least a portion of said substantially planar zones; and further including a sample application zone laminated onto at least a portion of said chromatographing section and in adsorptive contact therewith.
27. A device as claimed in claim 18, wherein all or some of be reagents required for the detection of the labelling are present in one or more of the substantially planar zones of the device.
28. A device as claimed in claim 18, wherein said layer includes a chromotographing section in at least a portion of said substantially planar zones, and further including a reagent zone laminated onto at least a portion of said chromotographing section and in adsorptive contact therewith, wherein at least some of the reagents required for the detection of the labelling are present in said reagent zone.
29. A process for the detection or determination of a component in a fluid as an analyte with bioaffinity binding properties by rehydrating or solvating reactants and reagents by the fluid containing the analyte or by an additional fluid, said reactants and reagents being present in a dehydrated state in an analytical device for the detection or determination of the analyte, said device including a layer of a plurality of substantially planar zones adjacent one another and in absorbent contact with one another, said layer including:
a mobile phase application zone (MPAZ), an intermediate zone (IZ) and an adsorption zone (AZ), liquid being capable of moving by adsorption from said MPAZ through said IZ to said AZ;
a solid phase zone (SPZ) in said IZ capable of having at least one unlabelled reactant fixed thereto which is capable of interactions of bioaffinity with at least one analyte, during analysis said at least one unlabelled reactant being fixed to at least one second reactant which is fixed to said solid phase zone;
at least one unattached labelled reactant (conjugate), capable of interactions of biological affinity with said at least one analyte, disposed in a zone between the MPAZ and the SPZ; and
an analyte application zone disposed at said MPAZ or in between said MPAZ and said AZ;
said process comprising:
applying a sample to said analyte application zone, reacting be at least one analyte in the sample in said layer and detecting said at least one analyte in said layer.
30. The process as claimed in claim 29, wherein, after the liquid sample containing the analyte has been fed to the MPAZ or after the sample has been fed to a sample application zone and a mobile phase has been fed to the MPAZ, the liquid reaches the end of the AZ, under the control of capillary forces, and reactions between reactants contained in the device and the analyte are thereby set in operation, and, after the labelled reactants which are not attached to the solid phase have been removed chromatographically, the amount of the labelling in the solid phase zone, which is a measure of the analyte concentration in the sample, is determined.
31. The process as claimed in claim 29, wherein the reactions taking place in the device are based on the principals of at least one of immunological detection reactions, competitive immunometric or sandwich immunoassay, indirect antibody detection by means of a labelled antibody and antibody detection by means of a labelled antigen.
32. The process as claimed in claim 29, wherein said detecting includes using a fluorophor as a labelling agent which is detected or measured directly or is detected or measured after the addition of a reagent present in the device, or a fluorophor which is detected or measured directly or after the addition of a further reagent is formed from the labelling agent by the addition of a reagent present in the device.
33. The process as in claim 29, wherein said detecting includes using a compound which can be excited to give chemiluminescence as a labelling agent, the chemiluminescence being detectable or measurable after the addition of a reagent present in the device.
34. The process as claimed in claim 29, wherein said detecting includes using an enzyme as a labelling agent, the activity of which is determined with the aid of a reagent present in the device.
US08/544,579 1984-12-15 1995-10-18 Sheet-like diagnostic device Expired - Lifetime USRE37437E1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US08/544,579 USRE37437E1 (en) 1984-12-15 1995-10-18 Sheet-like diagnostic device
US09/820,974 USRE38688E1 (en) 1984-12-15 2001-03-30 Sheet-like diagnostic device

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE3445816A DE3445816C1 (en) 1984-12-15 1984-12-15 Flat diagnostic agent
DE3445816 1984-12-15
US06/808,563 US4861711A (en) 1984-12-15 1985-12-13 Sheet-like diagnostic device
US08/544,579 USRE37437E1 (en) 1984-12-15 1995-10-18 Sheet-like diagnostic device

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US06/808,563 Reissue US4861711A (en) 1984-12-15 1985-12-13 Sheet-like diagnostic device

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US06/808,563 Continuation US4861711A (en) 1984-12-15 1985-12-13 Sheet-like diagnostic device

Publications (1)

Publication Number Publication Date
USRE37437E1 true USRE37437E1 (en) 2001-11-06

Family

ID=6252876

Family Applications (3)

Application Number Title Priority Date Filing Date
US06/808,563 Ceased US4861711A (en) 1984-12-15 1985-12-13 Sheet-like diagnostic device
US08/544,579 Expired - Lifetime USRE37437E1 (en) 1984-12-15 1995-10-18 Sheet-like diagnostic device
US09/820,974 Expired - Lifetime USRE38688E1 (en) 1984-12-15 2001-03-30 Sheet-like diagnostic device

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US06/808,563 Ceased US4861711A (en) 1984-12-15 1985-12-13 Sheet-like diagnostic device

Family Applications After (1)

Application Number Title Priority Date Filing Date
US09/820,974 Expired - Lifetime USRE38688E1 (en) 1984-12-15 2001-03-30 Sheet-like diagnostic device

Country Status (10)

Country Link
US (3) US4861711A (en)
EP (1) EP0186799B2 (en)
JP (2) JPH0778503B2 (en)
AT (1) ATE50457T1 (en)
AU (1) AU600657B2 (en)
CA (1) CA1267083A (en)
DE (2) DE3445816C1 (en)
ES (1) ES8607556A1 (en)
MX (1) MX173718B (en)
YU (1) YU45751B (en)

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030077673A1 (en) * 2001-10-19 2003-04-24 Matsushita Electric Industrial Co., Ltd. Specific binding analysis method and device used therefor
US20030190759A1 (en) * 2002-04-05 2003-10-09 Matsushita Electric Industrial Co., Ltd. Specific bonding analysis method and device therefor
US20040029293A1 (en) * 2002-06-07 2004-02-12 Nugent Anthony J. Automated immunoassay cassette, apparatus and method
WO2004097419A1 (en) * 2003-04-25 2004-11-11 Biodigit Laboratories Corp. Membrane strip biosensor system for point-of-care testing
US6824997B1 (en) * 1998-09-18 2004-11-30 Binax, Inc. Process and materials for the rapid detection of streptococcus pneumoniae employing purified antigen-specific antibodies
US20050147532A1 (en) * 2002-06-07 2005-07-07 Bellet Neal F. Automated immunoassay cassette, apparatus and method
US20060105406A1 (en) * 2001-04-25 2006-05-18 Rockeby Biomed (Australia) Pty. Ltd. Cytoplasmic antigens for detection of Candida
US20060211071A1 (en) * 2004-12-14 2006-09-21 Millennium Pharmaceuticals, Inc. Device for aggregating, imaging and analyzing thrombi and a method of use
US20080096236A1 (en) * 1998-08-25 2008-04-24 Binax, Inc. Method for Detecting the Presence of Target Bacteria or a Target Component Carbohydrate Antigen Thereof
US7682801B2 (en) 2005-03-11 2010-03-23 Chembio Diagnostic Systems, Inc. Dual path immunoassay device
US7795038B2 (en) 2002-04-09 2010-09-14 Cholestech Corporation High-density lipoprotein assay device and method
US7824879B2 (en) 2007-01-09 2010-11-02 Cholestech Corporation Device and method for measuring LDL-associated cholesterol
US7879597B2 (en) 2005-03-11 2011-02-01 Chembio Diagnostic Systems, Inc. Dual path immunoassay device
US8603835B2 (en) 2011-02-10 2013-12-10 Chembio Diagnostic Systems, Inc. Reduced step dual path immunoassay device and method
US20150192581A1 (en) * 2009-11-23 2015-07-09 Yeshiva University Lateral Flow Device for Diagnosing Microbial Infections
US9134303B1 (en) 1998-08-25 2015-09-15 Alere Scarborough, Inc. ICT immunoassay for Legionella pneumophila serogroup 1 antigen employing affinity purified antibodies thereto
US9414813B2 (en) 2009-02-16 2016-08-16 Express Diagnostics Int'l, Inc. Device for assaying analytes in bodily fluids
US9885710B2 (en) 2014-04-02 2018-02-06 Chembio Diagnostic Systems, Inc. Immunoassay utilizing trapping conjugate
US10690667B2 (en) 2014-10-27 2020-06-23 Chembio Diagnostic Systems, Inc. Rapid screening assay for qualitative detection of multiple febrile illnesses
US11079380B2 (en) 2009-11-23 2021-08-03 The Johns Hopkins University Optimizing diagnostics for galactofuranose containing antigens
US11350913B2 (en) 2008-07-24 2022-06-07 Chembio Diagnostic Systems, Inc. Method and apparatus for collecting and preparing biological samples for testing

Families Citing this family (259)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5622871A (en) 1987-04-27 1997-04-22 Unilever Patent Holdings B.V. Capillary immunoassay and device therefor comprising mobilizable particulate labelled reagents
US6472160B2 (en) * 1919-09-08 2002-10-29 Fujirebio Inc. Immunoassay device and immunoassay method using the same
US5073484A (en) * 1982-03-09 1991-12-17 Bio-Metric Systems, Inc. Quantitative analysis apparatus and method
DE3445816C1 (en) 1984-12-15 1986-06-12 Behringwerke Ag, 3550 Marburg Flat diagnostic agent
US4740468A (en) * 1985-02-14 1988-04-26 Syntex (U.S.A.) Inc. Concentrating immunochemical test device and method
GB8526741D0 (en) * 1985-10-30 1985-12-04 Boots Celltech Diagnostics Binding assay device
US5500350A (en) * 1985-10-30 1996-03-19 Celltech Limited Binding assay device
CA1289872C (en) * 1986-06-18 1991-10-01 David L. Woodrum Reversible immobilization of assay reagents in a multizone test device
DE3722273A1 (en) * 1986-07-08 1988-01-21 Bio Rad Laboratories SOLID PHASE BINDING REAGENTS, THEIR PRODUCTION AND ASSAY KITS CONTAINING THEM
US5260193A (en) * 1986-09-05 1993-11-09 Syntex (U.S.A.) Inc. Immunoseparating strip
US4959307A (en) * 1986-09-05 1990-09-25 Syntex (U.S.A.) Inc. Immunoseparating strip
US5085987A (en) * 1986-09-05 1992-02-04 Syntex (U.S.A.) Inc. Immunoseparating strip
US5260194A (en) * 1986-09-05 1993-11-09 Syntex (U.S.A.) Inc. Immunoseparating strip
US4963468A (en) * 1986-09-05 1990-10-16 Syntex (U.S.A.) Inc. Immunoseparating strip
US5085988A (en) * 1986-09-05 1992-02-04 Syntex (U.S.A.) Inc. Immunoseparating strip
US4960691A (en) * 1986-09-29 1990-10-02 Abbott Laboratories Chromatographic test strip for determining ligands or receptors
DE3643516A1 (en) * 1986-12-19 1988-06-30 Boehringer Mannheim Gmbh TEST CARRIER FOR THE ANALYTICAL DETERMINATION OF INGREDIENTS OF BODY LIQUIDS
ES2004066A6 (en) * 1987-01-21 1988-12-01 Euro Fassel Aktiebolag A kit for qualitative and quantitative analysis of antigens, antibodies and/or microorganisms or other cells
US5079142A (en) * 1987-01-23 1992-01-07 Synbiotics Corporation Orthogonal flow immunoassays and devices
USRE38430E1 (en) 1987-03-27 2004-02-17 Becton, Dickinson And Company Solid phase chromatographic immunoassay
JP2564540B2 (en) * 1987-04-01 1996-12-18 株式会社日立製作所 Immunoassay method
US4857453A (en) * 1987-04-07 1989-08-15 Syntex (U.S.A.) Inc. Immunoassay device
JPH0746107B2 (en) 1987-04-27 1995-05-17 ユニリーバー・ナームローゼ・ベンノートシヤープ Test method
ATE86386T1 (en) * 1987-04-29 1993-03-15 Celltech Ltd DEVICE FOR BINDING TEST.
US5641639A (en) * 1987-04-29 1997-06-24 Celltech Therapeutics Limited Binding assay device
US4855240A (en) * 1987-05-13 1989-08-08 Becton Dickinson And Company Solid phase assay employing capillary flow
CA1313616C (en) * 1987-06-01 1993-02-16 Robert B. Sargeant Lateral flow, non-bibulous membrane protocols
US4999287A (en) * 1988-05-19 1991-03-12 Chemtrak Corporation Direct measuring assay strip and method of use thereof
US5120643A (en) * 1987-07-13 1992-06-09 Abbott Laboratories Process for immunochromatography with colloidal particles
IT1223295B (en) * 1987-08-14 1990-09-19 Boehringer Biochemia Srl IMMUNODIAGNOSTIC DEVICE AND METHOD
US4981786A (en) * 1987-09-04 1991-01-01 Syntex (U.S.A.) Inc. Multiple port assay device
US4956302A (en) * 1987-09-11 1990-09-11 Abbott Laboratories Lateral flow chromatographic binding assay device
DE3879048T2 (en) * 1987-09-11 1993-09-02 Abbott Lab DEVICE FOR LATERAL IMMUNOCHROMATOGRAPHIC DETERMINATION.
GB8725458D0 (en) * 1987-10-30 1987-12-02 Unilever Plc Chemical testing
US5275785A (en) * 1987-10-30 1994-01-04 Unilever Patent Holdings B.V. Test device for detecting an analyte in a liquid sample
EP0323605B1 (en) * 1987-12-21 1994-01-26 Abbott Laboratories Chromatographic binding assay devices and methods
US5104793A (en) * 1988-02-16 1992-04-14 Boehringer Mannheim Corporation Method for determining an analyte in a liquid sample using a zoned test device and an inhibitor for a label used in said method
US5334513A (en) * 1988-05-17 1994-08-02 Syntex (U.S.A.) Inc. Method for immunochromatographic analysis
AU2684488A (en) 1988-06-27 1990-01-04 Carter-Wallace, Inc. Test device and method for colored particle immunoassay
JPH0238971A (en) * 1988-07-29 1990-02-08 Nitto Denko Corp Reagent for enzyme immunoassay and enzyme immunoassay using this reagent
DE3826057A1 (en) * 1988-07-30 1990-02-01 Boehringer Mannheim Gmbh TEST TESTER FOR THE ANALYTICAL DETERMINATION OF AN INGREDIENT OF A LIQUID SAMPLE
US5338513A (en) * 1988-07-30 1994-08-16 Boehringer Mannheim Gmbh Test carrier for the analytical determination of a component of a liquid sample
DE3842702A1 (en) * 1988-12-19 1990-06-21 Boehringer Mannheim Gmbh TEST CARRIER FOR ANALYTICAL EXAMINATION OF A SAMPLING LIQUID WITH THE AID OF A SPECIFIC BINDING REACTION OF TWO BIOAFFIN BINDING PARTNERS AND A CORRESPONDING TEST PROCEDURE
GB8903627D0 (en) * 1989-02-17 1989-04-05 Unilever Plc Assays
US6352862B1 (en) 1989-02-17 2002-03-05 Unilever Patent Holdings B.V. Analytical test device for imuno assays and methods of using same
DE3905954C2 (en) * 1989-02-25 2001-02-01 Lohmann Therapie Syst Lts Process for the visualization of substance stains on layer chromatograms
IE69047B1 (en) * 1989-03-23 1996-08-07 Gary Harold Gregory Hen Thorpe Liquid transfer devices
US5260222A (en) * 1989-11-27 1993-11-09 Syntex (U.S.A.) Inc. Device and method for completing a fluidic circuit which employs a liquid expandable piece of bibulous material
US5135873A (en) * 1989-11-27 1992-08-04 Syntex (U.S.A.) Inc. Device and method for completing a fluidic circuit which employs a liquid expandable piece of bibulous material
US5620657A (en) * 1989-11-27 1997-04-15 Behringwerke Ag Device and method for completing a fluidic circuit
US5252496A (en) * 1989-12-18 1993-10-12 Princeton Biomeditech Corporation Carbon black immunochemical label
US5141850A (en) * 1990-02-07 1992-08-25 Hygeia Sciences, Inc. Porous strip form assay device method
DE4015378A1 (en) * 1990-05-14 1991-11-21 Boehringer Mannheim Gmbh TEST CARRIER FOR THE ANALYTICAL DETERMINATION OF A COMPONENT OF A SAMPLING LIQUID
DE4024544A1 (en) * 1990-08-02 1992-02-06 Boehringer Mannheim Gmbh ANALYZING ELEMENT AND METHOD FOR THE PRODUCTION THEREOF
DE69126142T2 (en) * 1990-09-26 1997-09-11 Akers Lab Inc IMPROVED LIGAND DETERMINATION PROCEDURE
WO1992012428A1 (en) * 1991-01-11 1992-07-23 Quidel Corporation A one-step lateral flow nonbibulous assay
JP3108115B2 (en) * 1991-03-28 2000-11-13 ロート製薬株式会社 Substance detection method by immunochromatography
US5869345A (en) * 1991-05-29 1999-02-09 Smithkline Diagnostics, Inc. Opposable-element assay device employing conductive barrier
US6168956B1 (en) 1991-05-29 2001-01-02 Beckman Coulter, Inc. Multiple component chromatographic assay device
US5998220A (en) 1991-05-29 1999-12-07 Beckman Coulter, Inc. Opposable-element assay devices, kits, and methods employing them
US5468648A (en) * 1991-05-29 1995-11-21 Smithkline Diagnostics, Inc. Interrupted-flow assay device
US5607863A (en) * 1991-05-29 1997-03-04 Smithkline Diagnostics, Inc. Barrier-controlled assay device
US5877028A (en) 1991-05-29 1999-03-02 Smithkline Diagnostics, Inc. Immunochromatographic assay device
US5686315A (en) * 1991-06-14 1997-11-11 Quidel Corporation Assay device for one step detection of analyte
US5451504A (en) * 1991-07-29 1995-09-19 Serex, Inc. Method and device for detecting the presence of analyte in a sample
US5540888A (en) * 1991-11-11 1996-07-30 British Technology Group Limited Liquid transfer assay devices
JP2500335B2 (en) * 1991-11-14 1996-05-29 農林水産省農業研究センター所長 Method for detecting trace substances in plants or on plant surface
JPH07503540A (en) * 1992-01-22 1995-04-13 アボツト・ラボラトリーズ Calibration reagents and equipment for semi-quantitative binding assays
DE4202848A1 (en) * 1992-01-31 1993-08-05 Boehringer Mannheim Gmbh ANALYSIS ELEMENT FOR IMMUNOASSAYS
DE4202850A1 (en) * 1992-01-31 1993-08-05 Boehringer Mannheim Gmbh ANALYSIS ELEMENT FOR IMMUNOASSAYS
JP2948318B2 (en) * 1992-03-10 1999-09-13 クイデル コーポレイション Red blood cell separation method for specific binding assays
US6100099A (en) * 1994-09-06 2000-08-08 Abbott Laboratories Test strip having a diagonal array of capture spots
JPH07509059A (en) * 1992-07-02 1995-10-05 クイデル コーポレイション Immunoassay using dye-conjugated enzyme conjugates
US5958339A (en) * 1992-08-31 1999-09-28 Clinical Diagnostic Systems, Inc. Format for immunoassay in thin film
AU659754B2 (en) * 1992-09-04 1995-05-25 Becton Dickinson & Company Chromatographic antigen sandwich test for detection of specific antibody and device therefor
AU660837B2 (en) * 1992-09-04 1995-07-06 Becton Dickinson & Company Indirect chromatographic antigen sandwich test for detection of specific antibody and device therefor
US5354692A (en) * 1992-09-08 1994-10-11 Pacific Biotech, Inc. Analyte detection device including a hydrophobic barrier for improved fluid flow
US5736410A (en) * 1992-09-14 1998-04-07 Sri International Up-converting reporters for biological and other assays using laser excitation techniques
US6399397B1 (en) * 1992-09-14 2002-06-04 Sri International Up-converting reporters for biological and other assays using laser excitation techniques
FI92882C (en) * 1992-12-29 1995-01-10 Medix Biochemica Ab Oy Disposable test strip and process for its manufacture
US5500375A (en) * 1993-04-13 1996-03-19 Serex, Inc. Integrated packaging-holder device for immunochromatographic assays in flow-through or dipstick formats
JP3479100B2 (en) 1993-06-02 2003-12-15 帝国臓器製薬株式会社 Simple semi-quantitative immunochemical method and apparatus
JPH08511621A (en) * 1993-06-09 1996-12-03 クイデル コーポレイション Antigen-specific one-step assay
US5837546A (en) * 1993-08-24 1998-11-17 Metrika, Inc. Electronic assay device and method
US5597700A (en) * 1994-04-28 1997-01-28 California Research, Llc Method for detecting free insulin-like growth-factor-binding protein 1 and a test device for detecting the ruptures of fetal membranes using the above method
US5658747A (en) * 1994-05-10 1997-08-19 Biocontrol System, Inc. Compositions and methods for control of reactivity between diagnostic reagents and microorganisms
WO1995032414A1 (en) * 1994-05-20 1995-11-30 Chemtrak, Inc. Qualitative surface immunoassay using consecutive reagent application
US6653066B1 (en) 1994-06-17 2003-11-25 Trinity Biotech Device and method for detecting polyvalent substances
EP0699906B1 (en) 1994-07-25 2002-04-24 Roche Diagnostics GmbH Method for detecting the contamination of a surface with an analyte
GB9416002D0 (en) * 1994-08-08 1994-09-28 Univ Cranfield Fluid transport device
DK0703454T3 (en) * 1994-09-23 2002-04-02 Unilever Nv Methods of monitoring and devices for use therewith
JP3010699U (en) * 1994-10-29 1995-05-02 株式会社ニッポンジーン Chromatographic inspection device capable of direct urine collection
CA2167362A1 (en) * 1995-02-10 1996-08-11 Alexei Dmitri Klimov Apparatus and method for conducting a binding assay on an absorbent carrier material
US5712172A (en) 1995-05-18 1998-01-27 Wyntek Diagnostics, Inc. One step immunochromatographic device and method of use
US5804452A (en) * 1995-04-27 1998-09-08 Quidel Corporation One step urine creatinine assays
US20010051350A1 (en) * 1995-05-02 2001-12-13 Albert Nazareth Diagnostic detection device and method
US5739041A (en) * 1995-05-02 1998-04-14 Carter Wallace, Inc. Diagnostic detection device
AU6720096A (en) 1995-08-09 1997-03-05 Quidel Corporation Test strip and method for one step lateral flow assay
US7635597B2 (en) 1995-08-09 2009-12-22 Bayer Healthcare Llc Dry reagent particle assay and device having multiple test zones and method therefor
US5833923A (en) * 1995-12-22 1998-11-10 Universal Healthwatch, Inc. Sampling-assay interface system
US5833924A (en) * 1995-12-22 1998-11-10 Universal Healthwatch, Inc. Sampling-assay device and interface system
ATE234467T1 (en) * 1996-03-14 2003-03-15 Spectral Diagnostics Inc IMMUNOASSAY OF WHOLE BLOOD SAMPLES
DE19611347A1 (en) * 1996-03-22 1997-09-25 Boehringer Mannheim Gmbh System for the quantitative, spatially resolved evaluation of test elements
US5900379A (en) * 1996-04-11 1999-05-04 Mizuho Usa, Inc. Analytical device
JP3026549B2 (en) 1996-05-02 2000-03-27 ダイナボット株式会社 Manufacturing method of chromatography immunoanalyzer
US5821073A (en) * 1996-05-09 1998-10-13 Syntron Bioresearch, Inc. Method and apparatus for single step assays of whole blood
US5968839A (en) * 1996-05-13 1999-10-19 Metrika, Inc. Method and device producing a predetermined distribution of detectable change in assays
US5945345A (en) * 1996-08-27 1999-08-31 Metrika, Inc. Device for preventing assay interference using silver or lead to remove the interferant
US6001658A (en) * 1996-09-13 1999-12-14 Diagnostic Chemicals Limited Test strip apparatus and method for determining presence of analyte in a fluid sample
EP0941337B1 (en) 1996-11-08 2009-02-18 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Synthesis and purification of hepatitis c virus-like particles
US6979576B1 (en) * 1997-07-25 2005-12-27 Shu-Ching Cheng Methods of use of one step immunochromatographic device for Streptococcus A antigen
DE19649390A1 (en) 1996-11-29 1998-06-04 Boehringer Mannheim Gmbh Antigen-specific IgG detection
US5879951A (en) 1997-01-29 1999-03-09 Smithkline Diagnostics, Inc. Opposable-element assay device employing unidirectional flow
US20050101032A1 (en) * 1997-02-10 2005-05-12 Metrika, Inc. Assay device, composition, and method of optimizing assay sensitivity
US6924153B1 (en) * 1997-03-06 2005-08-02 Quidel Corporation Quantitative lateral flow assays and devices
JPH10253632A (en) * 1997-03-10 1998-09-25 Nissui Pharm Co Ltd Method, kit and device for analysis
US6593079B1 (en) 1997-03-10 2003-07-15 Roche Diagnostics Gmbh Method for simultaneous detection of HIV antigens and HIV antibodies
US6103536A (en) 1997-05-02 2000-08-15 Silver Lake Research Corporation Internally referenced competitive assays
US5939252A (en) 1997-05-09 1999-08-17 Lennon; Donald J. Detachable-element assay device
GB9709821D0 (en) * 1997-05-15 1997-07-09 Clinical Diagnostic Chemicals Allergy assay
US6258548B1 (en) 1997-06-05 2001-07-10 A-Fem Medical Corporation Single or multiple analyte semi-quantitative/quantitative rapid diagnostic lateral flow test system for large molecules
US6824985B1 (en) * 1997-09-09 2004-11-30 Bayer Corporation Formulation for reducing urea effect for immunochromatography assays using urine samples
US6046057A (en) 1997-10-24 2000-04-04 Carter-Wallace, Inc. Analyte assaying device
DE19816550A1 (en) * 1997-12-24 1999-06-24 Roche Diagnostics Gmbh Universally applicable structure of an analysis element and its use for analyte determination
SE9704933D0 (en) 1997-12-30 1997-12-30 Pharmacia & Upjohn Diag Ab Method utilizing a new calibrator and test kit containing the calibrator
US6394952B1 (en) 1998-02-03 2002-05-28 Adeza Biomedical Corporation Point of care diagnostic systems
US6267722B1 (en) 1998-02-03 2001-07-31 Adeza Biomedical Corporation Point of care diagnostic systems
WO1999040438A1 (en) * 1998-02-03 1999-08-12 Synbiotics Corporation Device and method to detect immunoprotective antibody titers
US6548309B1 (en) * 1998-03-19 2003-04-15 Binax, Inc. Procedure for assay of liquids containing undissolved solids, semisolids or colloids
AU757629B2 (en) * 1998-04-14 2003-02-27 Otsuka Pharmaceutical Co., Ltd. Methods for assaying antibody and device for assaying antibody
USD432244S (en) * 1998-04-20 2000-10-17 Adeza Biomedical Corporation Device for encasing an assay test strip
USD434153S (en) * 1998-04-20 2000-11-21 Adeza Biomedical Corporation Point of care analyte detector system
SE9801563D0 (en) * 1998-04-30 1998-04-30 Pharmacia & Upjohn Diag Ab Method of separation and kit to be used in the process
US20060029926A1 (en) * 1998-05-06 2006-02-09 Metrika, Inc. Blocking compositions for immunoassays
US6271044B1 (en) * 1998-05-06 2001-08-07 University Of Pittsburgh Of The Commonwealth System Of Higher Education Method and kit for detecting an analyte
DE19828466A1 (en) 1998-06-26 1999-12-30 Roche Diagnostics Gmbh Suppressor peptides derived from antibodies for use in immunoassays
GB2339615B (en) 1998-07-14 2001-02-07 Cozart Bioscience Ltd Screening device and method of screening an immunoassay test
US6171870B1 (en) 1998-08-06 2001-01-09 Spectral Diagnostics, Inc. Analytical test device and method for use in medical diagnoses
US6410341B1 (en) 1998-08-06 2002-06-25 Spectral Diagnostics, Inc. Analytical test device and method for use in medical diagnoses
ATE237807T1 (en) 1998-08-06 2003-05-15 Spectral Diagnostics Inc ANALYTICAL TEST APPARATUS AND METHOD
US6214629B1 (en) 1998-08-06 2001-04-10 Spectral Diagnostics, Inc. Analytical test device and method for use in medical diagnoses
GB9823397D0 (en) 1998-10-27 1998-12-23 Rsr Ltd Assays for thyroid autoantibodies
JP3395673B2 (en) 1998-11-18 2003-04-14 株式会社豊田中央研究所 Specific binding pair measurement method using micro oxygen electrode
US7297554B2 (en) * 1998-11-18 2007-11-20 Microdiagnostics, Inc. Immunoassay system
DE19912365A1 (en) 1999-03-19 2000-09-21 Roche Diagnostics Gmbh Multi-layer analytical tool
DE19927783A1 (en) 1999-06-18 2000-12-21 Roche Diagnostics Gmbh Element for determining an analyte in a liquid, corresponding determination method using the element and kit for determining an analyte
US6306665B1 (en) 1999-10-13 2001-10-23 A-Fem Medical Corporation Covalent bonding of molecules to an activated solid phase material
US6998273B1 (en) * 2000-02-09 2006-02-14 A-Fem Medical Corporation Collection device for lateral flow chromatography
US6365417B1 (en) 2000-02-09 2002-04-02 A-Fem Medical Corporation Collection device for lateral flow chromatography
US6699722B2 (en) 2000-04-14 2004-03-02 A-Fem Medical Corporation Positive detection lateral-flow apparatus and method for small and large analytes
JP3680090B2 (en) * 2000-05-25 2005-08-10 株式会社ニチレイ Analysis equipment
AU2001290309A1 (en) 2000-10-27 2002-05-15 International Reagents Corporation Method of diagnosing nephropathy
US6818392B2 (en) 2000-12-06 2004-11-16 Abbott Laboratories Monoclonal antibodies to human immunodeficiency virus and uses thereof
US20020102717A1 (en) * 2000-12-09 2002-08-01 Hadeed Erika Lynn Refillable, reusable pregnancy test
US20050266499A1 (en) * 2001-04-25 2005-12-01 Rockeby Biomed Corporation, Ltd. Method and apparatus for testing for presence or absence of select biological substances
US7291477B2 (en) 2001-07-03 2007-11-06 Xenotope Diagnostics, Inc. Method and device for trichomonas detection
US6723500B2 (en) * 2001-12-05 2004-04-20 Lifescan, Inc. Test strips having reaction zones and channels defined by a thermally transferred hydrophobic barrier
JP2004069397A (en) * 2002-08-02 2004-03-04 Nec Corp Analysis chip and analytical apparatus
ES2525318T3 (en) * 2002-10-11 2014-12-22 Zbx Corporation Diagnostic devices
CN101967190A (en) 2003-05-12 2011-02-09 霍夫曼-拉罗奇有限公司 Method of detecting probnp with a monoclonal antibody binding to the amino acids 38-44 of probnp
US7393697B2 (en) * 2003-06-06 2008-07-01 Advantage Diagnostics Corporation Diagnostic test for analytes in a sample
CN100483134C (en) * 2003-06-30 2009-04-29 希森美康株式会社 Device for immunochromatography
CN100483133C (en) * 2003-06-30 2009-04-29 希森美康株式会社 Sample pretreatment solution for immunological test and method for using the same
EP1519194A1 (en) 2003-09-24 2005-03-30 Roche Diagnostics GmbH Use of gfap for identification of intracerebral hemorrhage
DE10355731A1 (en) * 2003-11-28 2005-06-30 Roche Diagnostics Gmbh Analytical sandwich test to determine NT-proBNP
US7150995B2 (en) 2004-01-16 2006-12-19 Metrika, Inc. Methods and systems for point of care bodily fluid analysis
DE102004023402A1 (en) 2004-05-12 2005-12-08 Roche Diagnostics Gmbh Method for increasing the dynamic measuring range of, in particular immunological test elements based on specific binding reactions
JP4758341B2 (en) 2004-06-07 2011-08-24 デンカ生研株式会社 Chromatographic detector, inspection method and kit using the same
KR101035111B1 (en) * 2004-06-30 2011-05-19 주식회사 엘지생명과학 Immunoassay for Plasmodium falciparum and means used therefor
US20060040258A1 (en) * 2004-08-23 2006-02-23 Huiyan Guo Water-soluble conjugates and methods of preparation
US7465587B2 (en) * 2004-12-03 2008-12-16 Genzyme Corporation Diagnostic assay device
US9101927B2 (en) 2005-01-31 2015-08-11 Realbio Technologies Ltd. Multistep reaction lateral flow capillary device
US8614101B2 (en) * 2008-05-20 2013-12-24 Rapid Pathogen Screening, Inc. In situ lysis of cells in lateral flow immunoassays
US20060205090A1 (en) * 2005-03-14 2006-09-14 Newton Michael W Water-soluble conjugates for electrochemical detection
CA2608162C (en) * 2005-05-23 2013-11-12 Phadia Ab Two step lateral flow assay methods and devices
EP1896851B1 (en) * 2005-06-28 2013-08-21 ZBx Corporation Membrane array and analytical device
US8017103B2 (en) * 2005-07-01 2011-09-13 Board Of Regents, The University Of Texas System Methods and compositions to diagnose trichomonas infection
US20070015224A1 (en) * 2005-07-01 2007-01-18 Board Of Regents, The University Of Texas System Methods and compositions to diagnose Trichomonas infection
US20070015166A1 (en) * 2005-07-14 2007-01-18 Nilsen Thor W Lateral flow methods and devices for detection of nucleic acid binding proteins
US7439028B2 (en) * 2005-09-30 2008-10-21 Board Of Regents, The University Of Texas System Methods and compositions to correlate Trichomonas infection with prostate cancer
JP4934147B2 (en) 2005-12-08 2012-05-16 コリス バイオコンセプト Test equipment for rapid diagnosis
US7803567B2 (en) * 2005-12-09 2010-09-28 Board Of Regents, The University Of Texas System Methods and compositions for detecting trichomonas in a sample contacted with fixative
ATE425458T1 (en) 2006-01-14 2009-03-15 Hoffmann La Roche IMMUNOLOGICAL TEST ELEMENT WITH IMPROVED CONTROL ZONE
US7569396B1 (en) 2006-09-08 2009-08-04 Purplecow Llc Caffeine detection using internally referenced competitive assays
EP1916524A1 (en) 2006-09-27 2008-04-30 Roche Diagnostics GmbH Rotatable test element
US8101403B2 (en) 2006-10-04 2012-01-24 University Of Washington Method and device for rapid parallel microfluidic molecular affinity assays
CN101578520B (en) * 2006-10-18 2015-09-16 哈佛学院院长等 Based on formed pattern porous medium cross flow and through biometric apparatus, and preparation method thereof and using method
US20080138842A1 (en) * 2006-12-11 2008-06-12 Hans Boehringer Indirect lateral flow sandwich assay
US7919331B2 (en) * 2006-12-21 2011-04-05 Silver Lake Research Corporation Chromatographic test strips for one or more analytes
JP2008249339A (en) 2007-03-29 2008-10-16 Gc Corp Immunochromatography test tool
EP2072529A1 (en) 2007-12-21 2009-06-24 basisnote AG MHC rapid assay used for the customization of odours
US8206992B2 (en) * 2008-03-27 2012-06-26 President And Fellows Of Harvard College Cotton thread as a low-cost multi-assay diagnostic platform
US8921118B2 (en) * 2008-03-27 2014-12-30 President And Fellows Of Harvard College Paper-based microfluidic systems
CN101978272B (en) * 2008-03-27 2015-02-04 哈佛学院院长等 Paper-based cellular arrays
AU2009228091B2 (en) 2008-03-27 2015-05-21 President And Fellows Of Harvard College Three-dimensional microfluidic devices
US8303910B2 (en) * 2008-05-07 2012-11-06 Panasonic Corporation Biosensor
US8673644B2 (en) 2008-05-13 2014-03-18 Battelle Memorial Institute Serum markers for type II diabetes mellitus
US20130196310A1 (en) 2008-05-20 2013-08-01 Rapid Pathogen Screening, Inc. Method and Device for Combined Detection of Viral and Bacterial Infections
US8815609B2 (en) 2008-05-20 2014-08-26 Rapid Pathogen Screening, Inc. Multiplanar lateral flow assay with diverting zone
US8609433B2 (en) * 2009-12-04 2013-12-17 Rapid Pathogen Screening, Inc. Multiplanar lateral flow assay with sample compressor
US8962260B2 (en) 2008-05-20 2015-02-24 Rapid Pathogen Screening, Inc. Method and device for combined detection of viral and bacterial infections
US9797898B2 (en) 2008-05-20 2017-10-24 Rapid Pathogen Screening, Inc. Methods and devices for using mucolytic agents including N-acetyl cysteine (NAC)
US9068981B2 (en) 2009-12-04 2015-06-30 Rapid Pathogen Screening, Inc. Lateral flow assays with time delayed components
EP2326419B1 (en) 2008-06-29 2021-04-07 Realbio Technologies Ltd. Liquid transfer device particularly useful as a capturing device in a biological assay process
US8476008B2 (en) * 2008-07-23 2013-07-02 Diabetomics, Llc Methods for detecting pre-diabetes and diabetes
JP5487104B2 (en) 2008-08-22 2014-05-07 デンカ生研株式会社 Membrane assay test device with control display
EP2194381B1 (en) 2008-12-03 2015-12-02 Roche Diagnostics GmbH Testing element with combined control and calibration zone
AU2010208394A1 (en) 2009-01-27 2011-09-08 Hologic, Inc. Biomarkers for detection of neonatal sepsis in biological fluid
WO2010102279A1 (en) 2009-03-06 2010-09-10 President And Fellows Of Harvard College Microfluidic, electromechanical devices
GB0905519D0 (en) * 2009-03-31 2009-05-13 Biofortuna Ltd Assay method and device
JP5816613B2 (en) 2009-04-23 2015-11-18 ダブリン シティ ユニバーシティ Lateral flow analyzer and method for monitoring coagulation
US8168396B2 (en) 2009-05-11 2012-05-01 Diabetomics, Llc Methods for detecting pre-diabetes and diabetes using differential protein glycosylation
JP5781530B2 (en) 2009-11-25 2015-09-24 ホロジック,インコーポレイテッドHologic,Inc. Detection of intraamniotic infection
DE102010001032B4 (en) * 2010-01-19 2014-11-20 Merete Management Gmbh indicating means
US8821810B2 (en) 2010-02-03 2014-09-02 President And Fellows Of Harvard College Devices and methods for multiplexed assays
DE102010011838A1 (en) 2010-03-10 2011-09-15 Ulti Med Products International Gmbh Arrangement for determining presence and/or amount of e.g. analytes in samples of body fluids of human in hospital, has supply aperture supplying sample of body fluid of human, and screw thread article provided on housing
EP2550529B1 (en) 2010-03-23 2021-11-17 Iogenetics, LLC. Bioinformatic processes for determination of peptide binding
EP3050901B1 (en) 2010-04-09 2018-08-29 Critical Care Diagnostics, Inc. Soluble human st-2 antibodies and assays
CN103025885B (en) 2010-05-26 2016-01-20 伊利诺伊大学评议会 For detecting the individual glucose meter with quantitative wide region analyte
DE102010032718A1 (en) 2010-07-23 2012-01-26 Christoph Gienapp Device for determining presence or amount of human chorionic gonadotropin in e.g. blood, has line element on housing at region of window-like opening, and cooperating with window-like opening for displaying positive presence of analytes
US8956859B1 (en) 2010-08-13 2015-02-17 Aviex Technologies Llc Compositions and methods for determining successful immunization by one or more vaccines
US8486717B2 (en) 2011-01-18 2013-07-16 Symbolics, Llc Lateral flow assays using two dimensional features
WO2012178187A1 (en) 2011-06-23 2012-12-27 Paul Yager Reagent patterning in capillarity-based analyzers and associated systems and methods
EP2771349B1 (en) 2011-09-16 2020-02-26 Iogenetics, LLC. Bioinformatic processes for determination of peptide binding
ES2407055B1 (en) 2011-12-07 2014-04-16 Universidad Pablo De Olavide EMPLOYMENT OF ANTI-BETA-LACTOGLOBULIN ANTIBODIES IN THE DIAGNOSIS AND FOLLOW-UP OF CELIAC DISEASE
EP2794107B1 (en) 2011-12-22 2021-08-11 Life Technologies Corporation Sequential lateral flow capillary device for analyte determination
EP3418397B1 (en) 2012-01-24 2020-10-07 CD Diagnostics, Inc. System for detecting infection in synovial fluid
EP2812704A4 (en) 2012-02-07 2016-03-23 Intuitive Biosciences Inc Mycobacterium tuberculosis specific peptides for detection of infection or immunization in non-human primates
US9874556B2 (en) 2012-07-18 2018-01-23 Symbolics, Llc Lateral flow assays using two dimensional features
CN104937106A (en) 2012-11-21 2015-09-23 奥斯陆大学医院 Systems and methods for monitoring biological fluids
WO2014116756A1 (en) 2013-01-22 2014-07-31 University Of Washington Through Its Center For Commercialization Sequential delivery of fluid volumes and associated devices, systems and methods
US9052314B2 (en) 2013-03-14 2015-06-09 Silver Lake Research Corporation Biomarkers for detecting the presence of bacteria
CN105765384B (en) 2013-09-13 2018-02-09 Symbolics有限责任公司 Detected with the lateral chromatography of two dimension experiment and control signal readout mode
US9383352B2 (en) 2014-03-26 2016-07-05 Diabetomics, Inc. Salivary protein glycosylation test for diagnosis and monitoring of diabetes
DE102014007851B3 (en) * 2014-05-26 2015-11-12 Medion Grifols Diagnostics Ag Apparatus and method for the determination of blood group antigens with an incomplete antibody
US20180011088A1 (en) 2015-01-29 2018-01-11 Neogen Corporation Methods for Immuno Chromatographic Assay Desensitization
US9927443B2 (en) 2015-04-10 2018-03-27 Conquerab Inc. Risk assessment for therapeutic drugs
EP3286216B1 (en) 2015-04-23 2022-06-08 Nevada Research & Innovation Corporation Fungal detection using mannan epitope
CN108136051A (en) 2015-08-04 2018-06-08 Cd诊断股份有限公司 The method for detecting bad local organization reaction (ALTR) necrosis
US20170089893A1 (en) * 2015-09-24 2017-03-30 Globallergy, Llc Chromatographic immune assay for the detection of allergic sensitivities
US10808287B2 (en) 2015-10-23 2020-10-20 Rapid Pathogen Screening, Inc. Methods and devices for accurate diagnosis of infections
EP3371321A1 (en) 2015-11-06 2018-09-12 Oslo Universitetssykehus HF Methods and devices for detecting methanol poisoning using formate oxidase
EP3978619A1 (en) 2015-12-09 2022-04-06 Intuitive Biosciences, Inc. Automated silver enhancement system
WO2017147186A1 (en) 2016-02-22 2017-08-31 Ursure, Inc. System and method for detecting therapeutic agents to monitor adherence to a treatment regimen
US9903866B2 (en) 2016-04-05 2018-02-27 Conquerab Inc. Portable devices for detection of antibodies against therapeutic drugs
EP3442993B1 (en) 2016-04-13 2021-01-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and kits for the rapid detection of the escherichia coli o25b-st131 clone
US11651866B2 (en) 2016-10-17 2023-05-16 Reliant Immune Diagnostics, Inc. System and method for real-time insurance quote in response to a self-diagnostic test
US11579145B2 (en) 2016-10-17 2023-02-14 Reliant Immune Diagnostics, Inc. System and method for image analysis of medical test results
US11693002B2 (en) 2016-10-17 2023-07-04 Reliant Immune Diagnostics, Inc. System and method for variable function mobile application for providing medical test results using visual indicia to determine medical test function type
US10902951B2 (en) 2016-10-17 2021-01-26 Reliant Immune Diagnostics, Inc. System and method for machine learning application for providing medical test results using visual indicia
US9857372B1 (en) 2016-10-17 2018-01-02 Reliant Immune Diagnostics, LLC Arbovirus indicative birth defect risk test
US11802868B2 (en) 2016-10-17 2023-10-31 Reliant Immune Diagnostics, Inc. System and method for variable function mobile application for providing medical test results
US11061026B2 (en) 2017-02-17 2021-07-13 MFB Fertility, Inc. System of evaluating corpus luteum function by recurrently evaluating progesterone non-serum bodily fluids on multiple days
AU2018223316A1 (en) 2017-02-21 2019-07-25 Medicortex Finland Oy Non-invasive brain injury diagnostic device
WO2018203145A1 (en) 2017-05-03 2018-11-08 Oslo Universitetssykehus Hf Systems and methods for monitoring biological fluids
WO2019152657A1 (en) 2018-02-03 2019-08-08 Simple Healthkit, Inc. Reliable, comprehensive, and rapid sexual health assessment
US11300576B2 (en) 2019-01-29 2022-04-12 Arizona Board Of Regents On Behalf Of Arizona State University DARPin reagents that distinguish Alzheimer's disease and Parkinson's disease samples
DE102019117289A1 (en) 2019-06-27 2020-12-31 Katja Werner Carrier material, kit system and method for biological assays
WO2023242155A1 (en) 2022-06-14 2023-12-21 Janssen Vaccines & Prevention B.V. Compositions and methods for the diagnosis of hiv infection

Citations (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3620677A (en) 1961-12-18 1971-11-16 Miles Lab Indicating device
US3847553A (en) 1970-07-28 1974-11-12 Miles Lab Test for a given constituent in a liquid
GB1440464A (en) 1972-06-30 1976-06-23 Eastman Kodak Co Multilayer analytical elements
US4094647A (en) * 1976-07-02 1978-06-13 Thyroid Diagnostics, Inc. Test device
US4258001A (en) 1978-12-27 1981-03-24 Eastman Kodak Company Element, structure and method for the analysis or transport of liquids
EP0046004A1 (en) 1980-08-07 1982-02-17 Syva Company Concentrating zone method in heterogeneous immunoassays
US4361537A (en) 1979-01-12 1982-11-30 Thyroid Diagnostics, Inc. Test device and method for its use
EP0088636A2 (en) 1982-03-09 1983-09-14 Bio-Metrics Systems, Inc. Quantitative analysis apparatus and method
EP0097952A2 (en) 1982-06-30 1984-01-11 Fuji Photo Film Co., Ltd. Multilayer analytical element
EP0100619A1 (en) 1982-07-15 1984-02-15 Syva Company Enzyme chromatographic immunoassay
GB2126224A (en) 1982-08-20 1984-03-21 Midit Derivatives of ???-amino alkanoic acids
US4446232A (en) 1981-10-13 1984-05-01 Liotta Lance A Enzyme immunoassay with two-zoned device having bound antigens
US4447526A (en) * 1981-04-20 1984-05-08 Miles Laboratories, Inc. Homogeneous specific binding assay with carrier matrix incorporating specific binding partner
US4459358A (en) 1982-12-29 1984-07-10 Polaroid Corporation Multilayer element for analysis
US4472498A (en) 1981-07-24 1984-09-18 Fuji Photo Film Co., Ltd. Analysis film and a method of analysis using the same
US4496658A (en) * 1980-10-15 1985-01-29 Takeda Chemical Industries, Ltd. Method for enzyme immunoassay and production of antibody
CA1185882A (en) 1980-11-19 1985-04-23 Klaus Habenstein Analytical means
US4517288A (en) * 1981-01-23 1985-05-14 American Hospital Supply Corp. Solid phase system for ligand assay
US4594327A (en) 1983-11-02 1986-06-10 Syntex (U.S.A.) Inc. Assay method for whole blood samples
US4631174A (en) 1978-05-02 1986-12-23 Fuji Photo Film Co., Ltd. Multilayer chemical analysis member having an outer waterproof layer
US4690907A (en) * 1983-12-19 1987-09-01 Daiichi Pure Chemicals Co., Ltd. Capillary tube immunoassay
US4740468A (en) * 1985-02-14 1988-04-26 Syntex (U.S.A.) Inc. Concentrating immunochemical test device and method
US4756828A (en) 1984-04-12 1988-07-12 Syntex (U.S.A.) Inc. Chromatographic strip having non-compressed edges
US4757004A (en) 1984-03-16 1988-07-12 Syntex (U.S.A.) Inc. Chromatographic devices having modified edges
US4861711A (en) 1984-12-15 1989-08-29 Behringwerke Aktiengesellschaft Sheet-like diagnostic device
US5120643A (en) 1987-07-13 1992-06-09 Abbott Laboratories Process for immunochromatography with colloidal particles

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5934154A (en) 1982-08-19 1984-02-24 Konishiroku Photo Ind Co Ltd Determination by means of immunoanalytical element
US4496654A (en) 1983-04-08 1985-01-29 Quidel Detection of HCG with solid phase support having avidin coating
JPH0746107B2 (en) * 1987-04-27 1995-05-17 ユニリーバー・ナームローゼ・ベンノートシヤープ Test method
JP3226391B2 (en) * 1993-09-08 2001-11-05 株式会社小糸製作所 Automotive headlamp

Patent Citations (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3620677A (en) 1961-12-18 1971-11-16 Miles Lab Indicating device
US3847553A (en) 1970-07-28 1974-11-12 Miles Lab Test for a given constituent in a liquid
GB1440464A (en) 1972-06-30 1976-06-23 Eastman Kodak Co Multilayer analytical elements
US4094647A (en) * 1976-07-02 1978-06-13 Thyroid Diagnostics, Inc. Test device
US4631174A (en) 1978-05-02 1986-12-23 Fuji Photo Film Co., Ltd. Multilayer chemical analysis member having an outer waterproof layer
US4258001A (en) 1978-12-27 1981-03-24 Eastman Kodak Company Element, structure and method for the analysis or transport of liquids
US4361537A (en) 1979-01-12 1982-11-30 Thyroid Diagnostics, Inc. Test device and method for its use
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
EP0046004A1 (en) 1980-08-07 1982-02-17 Syva Company Concentrating zone method in heterogeneous immunoassays
US4366241B1 (en) 1980-08-07 1988-10-18
US4496658A (en) * 1980-10-15 1985-01-29 Takeda Chemical Industries, Ltd. Method for enzyme immunoassay and production of antibody
CA1185882A (en) 1980-11-19 1985-04-23 Klaus Habenstein Analytical means
US4517288A (en) * 1981-01-23 1985-05-14 American Hospital Supply Corp. Solid phase system for ligand assay
US4447526A (en) * 1981-04-20 1984-05-08 Miles Laboratories, Inc. Homogeneous specific binding assay with carrier matrix incorporating specific binding partner
US4472498A (en) 1981-07-24 1984-09-18 Fuji Photo Film Co., Ltd. Analysis film and a method of analysis using the same
US4446232A (en) 1981-10-13 1984-05-01 Liotta Lance A Enzyme immunoassay with two-zoned device having bound antigens
US5073484A (en) 1982-03-09 1991-12-17 Bio-Metric Systems, Inc. Quantitative analysis apparatus and method
EP0088636A2 (en) 1982-03-09 1983-09-14 Bio-Metrics Systems, Inc. Quantitative analysis apparatus and method
EP0097952A2 (en) 1982-06-30 1984-01-11 Fuji Photo Film Co., Ltd. Multilayer analytical element
EP0100619A1 (en) 1982-07-15 1984-02-15 Syva Company Enzyme chromatographic immunoassay
GB2126224A (en) 1982-08-20 1984-03-21 Midit Derivatives of ???-amino alkanoic acids
US4459358A (en) 1982-12-29 1984-07-10 Polaroid Corporation Multilayer element for analysis
US4594327A (en) 1983-11-02 1986-06-10 Syntex (U.S.A.) Inc. Assay method for whole blood samples
US4690907A (en) * 1983-12-19 1987-09-01 Daiichi Pure Chemicals Co., Ltd. Capillary tube immunoassay
US4757004A (en) 1984-03-16 1988-07-12 Syntex (U.S.A.) Inc. Chromatographic devices having modified edges
US4756828A (en) 1984-04-12 1988-07-12 Syntex (U.S.A.) Inc. Chromatographic strip having non-compressed edges
US4861711A (en) 1984-12-15 1989-08-29 Behringwerke Aktiengesellschaft Sheet-like diagnostic device
US4740468A (en) * 1985-02-14 1988-04-26 Syntex (U.S.A.) Inc. Concentrating immunochemical test device and method
US5120643A (en) 1987-07-13 1992-06-09 Abbott Laboratories Process for immunochromatography with colloidal particles

Non-Patent Citations (14)

* Cited by examiner, † Cited by third party
Title
European Patent Application of Fuji Photo Film Co., Ltd., Publication No. A2 0 097 952, dated Jan. 11, 1984. *
Hashimoto, Thin Layer Chromatography, pp. 1-4 (Hirokwawa Shoten 1962, Tokyo) (with English translation).
Hawkes et al., "A Dot-Immunobinding Assay for Monoclonal and Other Antibodies", Analytical Biochemistry, 119(1):142-147 (1982).
Maruzen, Experimental Chemistry Course 2 Fundamental Techniques II, pp. 215-216 (Japan Chemistry Society ed. 1956, Tokyo) (with English translation).
Maruzen, Experimental Chemistry Guidebook, pp. 218-219 (Japan Chemistry Society ed. 1984, Tokyo) (with English translation).
Nakamura, "General Principles of Immunoassays", Immunochemical Assays and Biosensor Technology for the 1990S, pp. 3-7 (Robert Nakamura ed., American Society for Microbiology 1992, Washington, D.C.).
Nanzand{overscore (o)}, Thin Layer Chromatography, pp. 40-41 (Masayuki Ishikawa et al. ed. 1963, Tokyo) (with English translation).
Suzuki, Tests in Thin Layer Chromatograpy-Hirokawa Chemical Series No. 3, pp. 18-20, (Hirokawa Shoten 1964, Tokyo) (with English translation).
Towbin et al., "Electrophoretic Transfer of Proteins from Polyacrylamide Gels to Nitrocellulose Sheets: Procedure and Some Applications", Proc. Natl. Acad. Sci., 76(9): 4350-4354 (1979).
van Raamosdonk et al., "Detection of Antigens and Antibodies by an Immuno-Peroxidase Method Applied on Thin Longitudinal Sections of SDS-Polyacrylamide Gels", J. Immunological Methods, 17:337-348 (1977).
West German Offenlegungschrift No. 30 43 608, dated Jun. 24, 1982.*
West German Offenlegungsschrift No. 33 29 628, dated Feb. 23, 1984*
West German Patentschrift No. 23 32 760, issued Mar. 4, 1982.*
Zuk et al., "Enzyme Immunochromatography-A Quantative Immunoassay Requiring No Instrumentation", Clin. Chem., 31(7):1144-1150 (1985).

Cited By (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080096236A1 (en) * 1998-08-25 2008-04-24 Binax, Inc. Method for Detecting the Presence of Target Bacteria or a Target Component Carbohydrate Antigen Thereof
US9989529B2 (en) 1998-08-25 2018-06-05 Alere Scarborough, Inc. Method for detection of Legionella bacteria employing purified antigen-specific antibodies
US9134303B1 (en) 1998-08-25 2015-09-15 Alere Scarborough, Inc. ICT immunoassay for Legionella pneumophila serogroup 1 antigen employing affinity purified antibodies thereto
US9921220B2 (en) 1998-09-18 2018-03-20 Alere Scarborough, Inc. Process and materials for the rapid detection of Streptococcus pneumoniae employing purified antigen-specific antibodies
US6824997B1 (en) * 1998-09-18 2004-11-30 Binax, Inc. Process and materials for the rapid detection of streptococcus pneumoniae employing purified antigen-specific antibodies
US9310369B2 (en) 1998-09-18 2016-04-12 Alere Scarborough, Inc. Process and materials for the rapid detection of Streptococcus pneumoniae employing purified antigen-specific antibodies
US20060105406A1 (en) * 2001-04-25 2006-05-18 Rockeby Biomed (Australia) Pty. Ltd. Cytoplasmic antigens for detection of Candida
US7537731B2 (en) 2001-10-19 2009-05-26 Panasonic Corporation Specific binding analysis device
US20090203152A1 (en) * 2001-10-19 2009-08-13 Panasonic Corporation Method for Analyzing an Analyte Qualitatively and Quantitatively
US8110147B2 (en) 2001-10-19 2012-02-07 Panasonic Corporation Method for analyzing an analyte qualitatively and quantitatively
US20030077673A1 (en) * 2001-10-19 2003-04-24 Matsushita Electric Industrial Co., Ltd. Specific binding analysis method and device used therefor
US20030190759A1 (en) * 2002-04-05 2003-10-09 Matsushita Electric Industrial Co., Ltd. Specific bonding analysis method and device therefor
US7795038B2 (en) 2002-04-09 2010-09-14 Cholestech Corporation High-density lipoprotein assay device and method
US20040029293A1 (en) * 2002-06-07 2004-02-12 Nugent Anthony J. Automated immunoassay cassette, apparatus and method
US20050147532A1 (en) * 2002-06-07 2005-07-07 Bellet Neal F. Automated immunoassay cassette, apparatus and method
US7220595B2 (en) 2002-06-07 2007-05-22 Cholestech Corporation Automated immunoassay cassette, apparatus and method
US7238519B2 (en) 2002-06-07 2007-07-03 Cholestech Corporation Automated immunoassay cassette, apparatus and method
WO2004097419A1 (en) * 2003-04-25 2004-11-11 Biodigit Laboratories Corp. Membrane strip biosensor system for point-of-care testing
US20060211071A1 (en) * 2004-12-14 2006-09-21 Millennium Pharmaceuticals, Inc. Device for aggregating, imaging and analyzing thrombi and a method of use
US7682801B2 (en) 2005-03-11 2010-03-23 Chembio Diagnostic Systems, Inc. Dual path immunoassay device
US9784734B2 (en) 2005-03-11 2017-10-10 Chembio Diagnostic Systems, Inc. Dual path immunoassay device
US7879597B2 (en) 2005-03-11 2011-02-01 Chembio Diagnostic Systems, Inc. Dual path immunoassay device
US8507259B2 (en) 2005-03-11 2013-08-13 Chembio Diagnostics Systems, Inc. Dual path immunoassay device
US8877450B2 (en) 2005-03-11 2014-11-04 Chembio Diagnostic Systems, Inc. Dual path immunoassay device
US7824879B2 (en) 2007-01-09 2010-11-02 Cholestech Corporation Device and method for measuring LDL-associated cholesterol
US11350913B2 (en) 2008-07-24 2022-06-07 Chembio Diagnostic Systems, Inc. Method and apparatus for collecting and preparing biological samples for testing
US9462998B2 (en) 2009-02-16 2016-10-11 Express Diagnostics Int'l, Inc. Device for assaying analytes in bodily fluids
US9414813B2 (en) 2009-02-16 2016-08-16 Express Diagnostics Int'l, Inc. Device for assaying analytes in bodily fluids
US10076314B2 (en) 2009-02-16 2018-09-18 Express Diagnostics Int'l, Inc. Device for assaying analytes in bodily fluids
US20150192581A1 (en) * 2009-11-23 2015-07-09 Yeshiva University Lateral Flow Device for Diagnosing Microbial Infections
US9915657B2 (en) * 2009-11-23 2018-03-13 Yeshiva Universtiy Lateral flow device for diagnosing microbial infections
US11079380B2 (en) 2009-11-23 2021-08-03 The Johns Hopkins University Optimizing diagnostics for galactofuranose containing antigens
US8603835B2 (en) 2011-02-10 2013-12-10 Chembio Diagnostic Systems, Inc. Reduced step dual path immunoassay device and method
US10473655B2 (en) 2014-04-02 2019-11-12 Chembio Diagnostic Systems, Inc. Immunoassay utilizing trapping conjugate
US10598657B2 (en) 2014-04-02 2020-03-24 Chembio Diagnostic Systems, Inc. Immunoassay utilizing trapping conjugate
US10908158B2 (en) 2014-04-02 2021-02-02 Chembio Diagnostic Systems, Inc. Immunoassay methods utilizing trapping conjugate
US10976315B2 (en) 2014-04-02 2021-04-13 Chembio Diagnostic Systems, Inc. Immunoassay utilizing trapping conjugate
US9885710B2 (en) 2014-04-02 2018-02-06 Chembio Diagnostic Systems, Inc. Immunoassay utilizing trapping conjugate
US9891216B2 (en) 2014-04-02 2018-02-13 Chembio Diagnostic Systems, Inc. Immunoassay methods utilizing trapping conjugate
US10690667B2 (en) 2014-10-27 2020-06-23 Chembio Diagnostic Systems, Inc. Rapid screening assay for qualitative detection of multiple febrile illnesses

Also Published As

Publication number Publication date
USRE38688E1 (en) 2005-01-18
MX173718B (en) 1994-03-23
EP0186799B1 (en) 1990-02-21
EP0186799B2 (en) 1993-10-20
CA1267083A (en) 1990-03-27
YU193685A (en) 1988-04-30
ATE50457T1 (en) 1990-03-15
YU45751B (en) 1992-07-20
EP0186799A1 (en) 1986-07-09
AU600657B2 (en) 1990-08-23
JPS61145459A (en) 1986-07-03
DE3576083D1 (en) 1990-03-29
ES549895A0 (en) 1986-05-16
JPH0755808A (en) 1995-03-03
JP2504923B2 (en) 1996-06-05
AU5131585A (en) 1986-06-19
JPH0778503B2 (en) 1995-08-23
US4861711A (en) 1989-08-29
ES8607556A1 (en) 1986-05-16
DE3445816C1 (en) 1986-06-12

Similar Documents

Publication Publication Date Title
USRE37437E1 (en) Sheet-like diagnostic device
USRE39664E1 (en) Lateral flow chromatographic binding assay device
EP0306772B1 (en) Lateral flow chromatographic binding assay device
US4517288A (en) Solid phase system for ligand assay
JP3009155B2 (en) Immunochromatographic analysis method
US5160486A (en) Test carrier utilizing reaction of two bioaffine binding partners
US7384796B2 (en) Assays
US3966897A (en) Medium for use in bioassay and method of using same
US5824268A (en) Rapid self-contained assay format
AU682071B2 (en) Analytical test device
US5716778A (en) Concentrating immunochemical test device and method
JP2930426B2 (en) Apparatus for performing one or more competitive immunoassays
JPS6250663A (en) Multi-zone analyzing testing tool with zone in which detectable signal concentrate
US5958339A (en) Format for immunoassay in thin film
US5266460A (en) Method of preparing immunological analytical element
JPS60249057A (en) One-stage heterogeneous assay
WO2004081528A2 (en) Assay device and method
JP2504923C (en)
USH1664H (en) Analytical element for immunoassay and method for its preparation
HRP940755A2 (en) Diagnostic device in the form of a sheet
WO2004081529A2 (en) Assay device and method

Legal Events

Date Code Title Description
AS Assignment

Owner name: BEHRING DIAGNOSTICS GMBH, GERMANY

Free format text: ;ASSIGNOR:BEHRINGWERKE AKTIENGESELLSCHAFT;REEL/FRAME:008792/0076

Effective date: 19970731

Owner name: BEHRING DIAGNOSTICS GMBH, GERMANY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BEHRINGWERKE AKTIENGESELLSCHAFT;REEL/FRAME:008842/0428

Effective date: 19970731

AS Assignment

Owner name: DADE BEHRING MARBURG GMBH, GERMANY

Free format text: CHANGE OF NAME;ASSIGNOR:BEHRING DIAGNOSTICS GMBH;REEL/FRAME:009197/0667

Effective date: 19980217

Owner name: DADE BEHRING MARBURG GMBH,GERMANY

Free format text: CHANGE OF NAME;ASSIGNOR:BEHRING DIAGNOSTICS GMBH;REEL/FRAME:009197/0667

Effective date: 19980217

FEPP Fee payment procedure

Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

AS Assignment

Owner name: DRESDNER BANK AKTIENGESELLSCHAFT IN FRANKFURT AM M

Free format text: GRANT OF SECURITY INTEREST IN UNITED STATES PATENTS, TRADEMARKS AND OTHER INTELLECTUAL PROPERTY RIGHTS;ASSIGNOR:DADE BEHRING MARBURG GMBH;REEL/FRAME:012333/0714

Effective date: 20011019

CC Certificate of correction
AS Assignment

Owner name: DADE BEHRING MARBURG GMBH, GERMANY

Free format text: RELEASE OF SECURITY INTEREST;ASSIGNOR:DRESDNER BANK AKTIENGESELLSCHAFT IN FRANKFURT AM MAIN;REEL/FRAME:017675/0358

Effective date: 20060407